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Abstract
Alkaline phosphatase (ALP) is a ubiquitously expressed enzyme, that has been 
shown to play a role in cell differentiation and organogenesis. One study has also 
demonstrated ALP activity in rat adipocytes. The purpose of the present study 
was therefore to determine whether ALP is expressed in preadipocytes and what 
role it may have in adipogenesis. ALP activity was detected in the murine 
preadipocyte cell line, 3T3-L1, and in human preadipocytes isolated from 
mammary tissue, and from subcutaneous abdominal fat depots. In all the cell 
types studied ALP activity increased in parallel with adipogenesis. In the 3T3 -L1 
cell line the tissue- non -specific ALP inhibitors, levamisole and histidine inhibited 
ALP activity, and adipogenesis, whereas the tissue specific ALP inhibitor Phe- 
Gly-Gly did not inhibit ALP or adipogenesis.
In human preadipocytes, histidine inhibited adipogenesis and ALP activity,
whereas levamisole inhibited adipogenesis, but did not block ALP
activity in intact cells. However, levamisole did inhibit ALP activity by 50% in cell
extracts. Levamisole was able to inhibit adipogenesis in human
preadipocytes. The tissue specific ALP inhibitor, Phe Gly Gly, did not
inhibit ALP activity or adipogenesis in human preadipocytes.
ALP activity and adipogenesis, were compared in preadipocytes isolated from 
mammary tissue taken from black (13) and white (15) female subjects. Both ALP 
activity and adipogenesis, were lower in white compared to black female 
subjects.
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Immunocytochemical, analysis of the 3T3-L1 cell line and human preadipocytes 
demonstrated that ALP activity was restricted to the lipid droplets of these cells.
ALP activity was also measured in serum samples obtained from 100 African 
subjects (74 females and 26 males) of varying BMI. ALP activity was found to be 
higher in obese than lean subjects, whereas, the other liver enzymes or products 
measured in serum were not. In fact these variables correlated to varying 
degrees with waist-hip ratio, whereas ALP levels did not. This suggest that liver 
function is predominantly influenced by abdominal obesity whereas serum ALP 
levels are more influenced by overall body adiposity.
In conclusion, ALP, may be involved in the control of adipogenesis, in the 3T3- 
L1 preadipocyte cell line and in human preadipocytes isolated from mammary 
adipose tissue and subcutaneous abdominal adipose tisssue. The presence of 
ALP activity in lipid droplets in 3T3-L1 cells and human preadipocytes, and the 
ability of ALP inhibitors to block adipogenesis strongly suggest that ALP plays a 
role in the control of adipogenesis.
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CHAPTER ONE
INTRODUCTION
Introduction
Obesity is defined as an excess accumulation of body fat associated with 
increased fat cell size and number. Obesity is a common and serious medical 
problem all over the world especially in industrial countries. Although obesity is 
associated with stigma in western countries, the public opinion of obesity and 
overweight in the Middle East is different being associated with health (i.e. a 
person is eating “well” and is also not HIV positive, which is associated with 
weight loss) and wealth. This is also the case in some African societies.
Obesity occurs when energy intake is greater than energy expenditure.
The surplus energy will be stored as fat in the adipose tissue. In the last decade, 
there has been a plethora of data relating to the fact that adipose cells are not 
just a storage depot for excess calories, but rather a metabolically active tissue 
Leptin and more recently, a number of additional cytokines have been reported to 
be secreted by adipocytes and to have paracrine as well as endocrine effects on 
a variety of target tissues .Relative to the issue of cytokines and insulin 
resistance .tumour necrosis factor a (TNFa ) has been reported to modify the 
insulin signalling pathway via serine phosphorylation of insulin receptor 
substrate-1 ,a primary substrate of the insulin receptor (Gregoire et al., 
1998;Fruhbeck et al., 2001).
Adipogenesis is the transformation of fibroblast like preadipocytes into 
mature adipocytes as a response to insulin and other metabolic processes. 
Although many of the molecular details about adipogenesis are still unknown,
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studies found many factors involved in this processes. Some stimulators include, 
peroxisome proliferator-activated receptor y (PPAR y), insulin-like growth factor I 
( IGF-I), Macrophage colony stimulating factor, fatty acids, prostaglandins and 
glucocorticoids. Inhibitors include glycoproteins, transforming growth factor- 
P(TGF-P), inflammatory cytokines and growth hormone (MacDougald and 
Mandrup, 2002). Beside those factors, there are others like age, gender, life style 
that may affect this process in one way or another (Friihbeck et al., 2001).
Obesity is associated with stress, incontinence , complications of pregnancy , 
menstrual irregularities , excess facial ha ir, increased surgical risk, and 
psychological disorders such as depression (Jung, 1997; Kopelman, 2000; 
Stevens , 2000), type 2 diabetes (Maggio and Pi-Sunyer, 2003; Must et al.,
1999), cardiovascular disease (Kannel et al., 1996; Lovejoy et al., 2001), sexual 
dysfunction (Hertz et al., 1979; Franks, 1998), and cancer (Flegal et al., 1998). 
Weight gain in adulthood is associated with significant increased mortality. 
Epidemiological evidence shows that the BMI associated with the lowest mortality 
falls within the range of 18.5-24.9, and that thinner people live longer than over 
weight and obese people (Stevens, 2000).
Adipogenesis could lead to central obesity if it occurs in the abdominal fat depot 
and peripheral obesity if it occurs in subcutaneous fat tissue .While the total 
number of adipocytes is increased with increasing fat mass, the increased 
number and percentage of large adipocytes may partially account for the inability
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of adipose tissue to function properly and this may contribute to some of the 
health problems associated with obesity (Rosen et al., 2000).
Many enzymes and hormones play major roles in adipogenesis and obesity. 
However the enzyme alkaline phosphatase (ALP) has not been studied for its 
role in adipogenesis and obesity. ALP is found in a number of different tissues, 
but its precise function in many of these tissues is not known. However it is 
thought that, ALP may play a role in cellullar differentiation and bone 
mineralization. Therefore, the present study was performed to determine whether 
ALP is expressed in human preadipocytes or the murine 3T3-L1 preadipocyte 
cell line and if so, whether it is involved in adipogenesis. Furthermore, because 
ethnic differences exist in the prevalence of obesity within different South African 
population group’s investigations were performed to determine whether ethnic 
differences are present in the level of adipogenesis.
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CHAPTER TWO
LITERATURE REVIEW
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Prevalence of obesity
Obesity is defined medically as a state of increased body weight, more 
specifically of increased fat tissue mass. It is associated with increased fat cells 
size and number, and usually is followed by serious health consequences if not 
controlled. The word obesity is derived from the Latin word obesus, which means 
fattened by eating. Body weight and composition, and the storage of energy as 
triglyceride in adipose tissue, are determined by the interaction between genetic, 
metabolic, environmental, and psychological factors. These influences ultimately 
act by changing the balance, between energy intake and expenditure 
(Spiegelman and Flier, 2001).
Any disorder in the energy balance can lead to obesity .The term 'obese' 
denotes excessive body weight relative to height. The most common medical 
assessment of obesity is body mass index (BMI) which is calculated based on 
body weight (measured in kilograms) divided by height (measured in 
meters),squared . People are considered overweight if they have a BMI 25-29.9, 
and they are considered obese if their BMI is more than 30 (Flegal et al., 1998). 
Some researchers divide obesity into three divisions according to the degree of 
obesity. When BMI is 30-35 the subject is considered to be obese, from 35-40 
very obese and the state of the BMI over 40 as severe obesity. See table 2.1.
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Table 2.1 WHO standard classification of obesity.
W H O  C lass ifica tion P opular Description B M I(kg /m 2) Risk o f co-m orb id ities
U nderw e ig h t Thin <18.5 Low
N orm al range Norm al 18.5-24.9 A verage
Pre-obese O verw eight 25-29.9 Increased
O bese C lass  1 O bese 30-34.9 M oderate
O bese  C lass II O bese 35-39.9 Severe
O bese C lass III M orbid ly O bese >40.0 Very severe
The World Health Organization ( WHO) reported in 2002 that the majority of 
adults in the United States are over w eight, with increasing numbers being 
clinically obese, and the trend is increasing .There are at least 300 million people 
worldwide who are clinically obese. Among these about half a million people die 
as result of obesity -related diseases every year in the Untied States and 
Canada(220,000 deaths) and in 20 countries of Western Europe (320,000 
deaths)(WHO , 2002).In the United States of America 65% of Americans were 
clinically overweight (Loos and Bouchard , 2003 ).
The World Institute reported in 2000 that, the number of overweight and obese 
people in the world was 1.1 billion (cited in Eckersley, 2001) .This year the WHO 
International Task Force (ITF )revealed that out of the world population of six 
billion there are 1.7 billion who are overweight or obese. Five of the top 10 global 
diseases identified by WHO are caused by obesity. More than 20% of European
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children between the age of five and seventeen are now considered to be 
overweight or obese. North Africa, the Middle East and Asia are seeing a marked 
rise in children's obesity, while the USA headed the list with more than 37%of 
children overweight or obese (cited in Abdel-Aziz, 2003).
Current data shows that the range of obesity prevalence in European countries is 
from 10% to 20% for men and 10% to 25% for women. Prevalence of obesity has 
increased by between 10-40% in the majority of European counties in the past 10 
years .The most dramatic increase has been in the UK where it has more than 
doubled between 1980 and 1995; from 6% to 15% among men and from 8% to 
17% among women, and has increased to 21% and 23.5% for men and women 
respectively in 2001 (National Audit Office, 2001). In USA the majority of adults 
are overweight with an increasing number being medically classified as obese. In 
Australia 67% of adult men and over 52% of the adult women are overweight or 
obese .Those figures in 1980 were 48% for adult men and 27% for adult women. 
The proportion of adult Australians who are obese has more than doubled over 
the past 20 years to 19% for men and 22% for women. Almost a quarter of 
Australian children and adolescent are over weight or obese (Cited in Eckersley, 
2001).
The impact of obesity has social and economic relevance. The economic cost of 
obesity in the USA is estimated to be $117 billion, about 52.3% of those costs via 
direct health care of obesity and 47.7% indirect costs which represent by lost 
wages because people are unable to work because of morbidity. Overweight and
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obesity is associated with higher risks of morbidity and premature death. There 
are more than 30 medical conditions associated with obesity (Colditz, 1999). 
Industrialisation and urbanisation have an important effect on the nutritional 
status of a population. It has lead to changes in lifestyle and diet. While these 
changes mean improvement in the standard of living, they also imply negative 
consequences such as unhealthy dietary patterns, diminishing physical activity 
and in parallel a growth in diet-related diseases.
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Figure 2.1 shows the prevalence of obesity in some countries, adapted from the 
The Global Challenge of Obesity and the International Obesity task force site 
page: www.iuns.org/features/obesity/tabfig.htm.
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USA
Australia
2030
Figure 2 shows the increasing prevalence of obesity to 2025. Adapted from 
Kopelman, 2000.
Obesity in South Africa
South Africa is one of the developing countries that have been hit by obesity. 
Emergence of obesity in South Africa began (at least in black society) after 1994, 
mainly because of urbanization. Moving of the population in this country from 
rural to the urban areas was associated with huge changes in life style. 
Availability of dense caloric and fatty food is also another important factor behind 
the increasing prevalence of obesity in this country.
In women, those who are older have a significantly higher level of obesity than 
their younger counterparts. The same effect is seen in urban women compared 
with non-urban women and African women who had significantly higher BMI than 
non-African females (Puoane et al., 2002). Abdominal obesity was found to be 
highest in white urban women and non urban African women .This type of obesity 
is known to have more adverse health consequences than peripheral obesity 
(Donahue et al., 1987).
Obesity in African societies is viewed positively as it is popular opinion that it 
reflects affluence and happiness. These opinions are obviously not born out by 
the many studies showing the increased morbidity and mortality associated with 
obesity. Obesity and overweight are also viewed by African populations as 
reflecting healthy people, as the high prevalence of HIV-AIDS in South Africa has 
lead to the common misbelief that weight loss and leanness are signifiers of HIV
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status and that being obese means you are not HIV positive. In some societies 
in South Africa obese and overweight women reflect the affluence of the men 
(Puoane et al., 2002).Researchers found that fat intake in African people 
increased from16% of the total calories in 1940 to 26% in 1990 to 30% in 2002 
(Fox, 1940 cited by Puoane et al., 2002).These reasons make the management 
and controlling of obesity in South Africa very difficult.
According to the Heart Foundation in South Africa, there are about 56.6% of 
women and 29.2% of men over weight or obese. Abdominal obesity is linked to 
hypertension and diabetes in studies done in South Africa (Steyn et al., 1996; 
Levitt et al., 1993). Obesity in South Africa emerges women in early years of life. 
Thus a 10% of women were obese at age of 15 to 24 years (Puoane et al., 
2002). In this a same study education was found to correlate positively with 
obesity, this was explained as the women with low education tend to do more 
manual work than their better educated counterparts. Table 2.2 provides a 
comparison of the rate of obesity from some African countries.
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C ountry Year A ges
(years)
Prevalence o f 
obesity  %
P revalence of 
obesity  %
Men W om en
Ghana 1987 >20 0.9
Mali 1991 >20 0.8
M auritius 1992 25 to 74 5 15
USA 1988-94 20 to 74 19.9 24.9
Tanzania 1986/89 35 to 64 0.6 3.6
South A frica
C ape Pen insu la , A fricans 1990 25 to 64 13.9 48.6
M angaung,A fricans 1990 25 to 64 12.9 43.9
Q w aQ w a, A fricans 1990 25 to 64 12.7 40.2
Cape Pen insu la ,M ixed 1982 25 to 64 7.2 31.4
South W estern  C ape,w h ites 1988 25 to 64 17.6 20.4
Durban, Indians 1990 25 to 69 3.5 17.6
D em ograph ic& H ealth  Survey .African 1998 15 7.7 30.5
D em ograph ic& H ealth  Survey .M ixed 1998 15 9.1 28.3
D em ograph ic& H ealth  Survey,A sian 1998 15 8.7 20.2
D em ograph ic& H ealth  Survey,W hites 1998
j
15 19.8 24.3
Table 2.2 Obesity Prevalence in South Africa and selected countries. Adapted 
from Puoane et al., 2002
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Causes of Obesity
Overeating
Overeating is an important factor in the pathophysiology of obesity. Any change 
in food intake over time can markedly alter the level of energy storage. Eating a 
diet with a high glycemic index has been suggested to increase total energy 
intake and to promote obesity (Ludwig, 2000) .Indeed for most obese individuals, 
overeating must be counted as the primary cause of obesity. Overeating causes 
hyperinsulinaemia, which promotes more weight gain.
Thus a vicious circle leads to increased weight gain and increased 
hyperinsulinaemia (Cosford, 1999). There are many factors affecting food intake, 
such as the price of food, the size of portions , the protein content, taste of food, 
the sweetness of food .fast foods, variety ,and accessibility of foods .Beside all 
these factors .some societies eat food according to special principles like halal 
and kosher food. From epidemiological studies however, evidence for a high-fat 
diet promoting a positive energy balance and development of obesity is not 
definitive (Seidell, 1998).
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Environmental Factors
The global epidemic of obesity is driven by an environment that encourages 
overeating and discourages physical activity, creating a consistent bias toward a 
positive energy balance. Environmental factors related to life style and cultural or 
socio-economic conditions are strong influences of obesity by influencing eating 
behaviour and physical activity .A marked change in BMI is frequently witnessed 
in migrant studies, where a population with common genetic heritage live under 
new environmental circumstances. Pima Indians, for example, living in the United 
States are on average 25 kg heavier than Pima Indians living in Mexico 
(Ravussin, 1995). A similar trend is seen for Africans living in the United States.
In Nigeria the mean of BMI for men is 21.7 and for women 22.6 while in the 
United States the BMI for the Nigerian men and women is 27.1 and 30.8 
respectively (cited in Kopelman 2000) .The same effect is observed in 
Aboriginals in Australia when they moved to urban areas (Thompson et al.,
2003).
Genetic Factors
Obesity tends to run in families, suggesting a genetic link. Studies on animals 
and humans suggest that genetic factors affect energy balance and thus may act 
as determinants of BMI. The genetics of human obesity has been evaluated 
mostly from twin studies, which led to the conclusion that there is a strong 
genetic factor. In one study the BMIs of adopted Danes were evaluated many 
years after adoption and compared with the BMIs of their biologic and adoptive
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parents. A correlation was observed between BMI at all levels of leanness and 
fatness between the biological parents and their offspring, who had been given 
up for adoption. This relationship was much weaker between children and their 
adoptive parents. These studies demonstrate that genetic factors are more 
important than environmental factors in determining body weight. Studies have 
confirmed the role of genetic predisposition in the aetiology of life-long obesity 
(Koeppen-Schomerus et al., 2001; Poulsen et al., 2001; Kunesova et al., 2002). 
If one of two parents is obese, the chances of their offspring developing obesity 
are 40%; if both parents were overweight all their lives, the chances increase to 
70% that the offspring will also be overweight (Adams and Murphy, 2000). More 
than 300 genes, markers, and chromosomal regions have been defined to be 
associated with human obesity phenotypes (Chagnon et al., 2003). The first 
monogenic human obesity syndrome was reported in 1997, and was congenital 
leptin deficiency. A study of two severely obese cousins was found to have 
undetectable levels of serum leptin (Montague et al., 1997a).
Psychological Factors
Psychological factors also influence eating habits. Many people eat in response 
to negative emotions such as boredom, sadness, or anger, and the development 
and perpetuation of some of the human obesities could have a largely 
psychological basis. Depression and some neurological problems can lead to 
overeating and obesity (Doll et al.2000; Rippe et al. 1998).
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1. Age
As a general rule as people grow older their metabolic rate slows down and they 
do not require as many calories to maintain their weight. If caloric intake remains 
constant or increases they will therefore gain weight (Ajlouni et al., 2000; Flagel 
et al., 1998).
2. Ethnic influence
Studies have shown differences in prevalence of obesity among different ethnic 
groups (Bjfjrntorp ,1993a;Flagel et al., 1998; Puoane et al., 2002;Swinburn et 
al.,1996).The interpretation of these differences have been attributed partly to the 
effect of obesity related genes, which becomes clear especially when individuals 
life style improved (WHO, 2000).The Asian Indians have high percentage of body 
fat in relation to body mass index and muscle mass, this accompanied with a 
proportionate increase in visceral fat (Banerji et al.,1999). Obesity and 
abdominal obesity are twice as prevalent in African American women compared 
with white women (Ferdinand, 2004). In a South African study it was found that 
old white men have the highest rate of obesity in men in South Africa (Puoane et 
al., 2002), whilst middle aged African females have the highest prevalence of 
obesity.
Some other factors related to overweight and obesity
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3. Educational level
There is a strong inverse association between obesity and educational status 
especially in women .This has been reported in many populations (Ajlouni et al., 
2001; Monteiro et al., 2001, Lipowicz, 2003). Ajlouni et al. (2001) found that the 
obesity is highly related to illiteracy in Jordan. Another study performed in Brazil 
found that in the less developed regions female obesity was negatively 
associated with education, and in a more developed regions obesity was also 
found to be associated negatively with education. In men it was found to be 
negatively associated with education, but to lesser degree than in women 
(Monteiro et al., 2001). Another study done by Lipowicz (2003) in the USA found 
that the level of education of the husband correlated negatively with the 
prevalence of obesity in the wives. This may be due to a higher level of education 
and economic status determining the dietary intake of the family, and an 
increased peer pressure to remain thin. In a study in South Africa (Puoane et al., 
2002) women with no education had lower BMIs than those with schooling 
.These women tend to do more manual labour than their better educated 
counterparts. The same study found that women with tertiary education had a 
lower BMI than those with some schooling.
4. Economic status
An Australian study showed that compared with middle and high socio-economic 
status, even after controlling for socio-economic differences in age and height, 
BMI was significantly higher among low socio-economic than middle and high
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socio-economic participants for the total group (O'Dxx, 2003).In urban areas of 
Brazil, over the period 1989-1997, increases in the prevalence of obesity have 
been relatively higher for the poorest population strata (Monterio et al., 2001).
5. Gender
Males have a higher resting metabolic rate than females, so males require more 
calories to maintain their body weight Studies have confirmed that women have 
more body fat than men (SjOstrom et al., 1972; Arner et al., 1991). Additionally 
when women become post-menopausal, their metabolic rate decreases 
significantly. That is part of the reason why many women start gaining weight 
after menopause. Studies found that women have a higher BMI than men, 
especially after the age of 50 year (Bjdrntop, 1993a; Flagel et al., 1998). Body 
composition differences also play an important role between genders. Men have 
more skeletal muscle than women, and these differences have been found to be 
very clear in the upper body (Janssen et al., 2000). Men also have more visceral 
fat than women (Albright and Stern, 1998).
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Obesity is a prevalent health hazard, especially in developed countries, and is 
associated with a number of pathological disorders, including hypertension, type 
2 diabetes mellitus, cardiovascular diseases, cancer, gallstones, respiratory 
system problems, and sleep apnoea. The degree of health impairment is 
determined by three factors: first is the amount of fat, second is the distribution of 
fat and third is the presence of other risk factors. The fat deposition may be 
generalized, or may occur preferentially in different adipose tissue compartments. 
Two major variants of obesity are distinguished for their different impact on 
morbidity of cardio-vascular diseases (CVD): truncal and peripheral obesity 
(Bray, 2003).
Predominant accumulation of fat in the truncal area, which includes 
subcutaneous and visceral fat divisions, is the main feature of android obesity. 
This form of obesity is more found in men and his associated with high risk for 
CVD, independent of generalized adiposity. While accumulation of fat in the 
gluteofemoral area is the main feature of gynoid obesity .This form of obesity is 
more frequently found in premenopausal women and apparently is not 
associated with increased risk for CVD (Bray, 2003).
Health risks associated with obesity
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Cardiovascular Hypertension, Coronary heart disease, Cerebrovascular disease 
Varicose veins, deep venous thrombosis, Hypertension
Respiratory Breathless, Sleep apnea, Hypoventilation syndrome
Gastrointestinal Hiatus hernia , Gallstones and cirrhosis, Hemorrhoids, Hernia, Cancer colorectal
Metabolic Hyperlipidaemia, Insulin resistance .Diabetes mellitus, Polycystic ovarian 
Syndrome
Neurology Nerve entrapment
Renal Proteinuria
Breast Breast cancer, Male gynaecomastia.
Uterus Endometrial cancer, Cervical cancer
Urological Prostate cancer, Stress incontinence
Skin Sweat rashes , fungal infection, Lymphodaema, Cellulitis, Acanthosis nigricans
Orthopaedic Osteoarthritis, Gout
Endocrine Growth hormone and IGF1 reduced , reduced prolactin response, 
Hyperdynamic ACTH response to CRH, Increased urinary free cortisol, Altered 
sex hormones
Pregnancy Obstetric complications, Caesarean operation, Large babies, Neural tube defects.
Table 2.3 Morbidity in obesity (adapted from Jung, 1997)
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The most prominent condition associated with obesity is hypertension. According 
to the WHO up to 20% of the population in developed countries may suffer from 
this condition (Cited in Baynes and Dominiczak, 2003).Obesity alone possibly 
accounts for 78% and 65% of essential hypertension in men and women 
respectively (Garrison et al,1987). Another study shows that 5-10% of obese 
patients have severe hypertension (Alexander, 1964-cited in Adams and Murphy,
2000). Some of the major characteristics associated with obesity associated 
hypertension in humans are the activation of the renin-angiotensin system (Hall 
et al., 2001; Hall and Louis, 1994; Domfeld et al., 1987), high levels of circulating 
leptin (Hall et al., 2002; Hirose, 1998), reduced growth hormone concentration 
and an activation of the sympathetic nervous system (Hall et al., 2001; Hall et al., 
2002). Figure 2.3 summarises the effect of obesity on blood pressure and renal 
and cardiovascular function.
Studies have shown that blood pressure is positively related to weight (Hirose, 
1998). The prevalence of high blood pressure in obese adults is 38.4 % for men 
and 32.2 % for women compared with 18.2 % for men and 16.5 % for women 
with BMI <25. Obesity, in some ethnic groups is not enough to cause 
hypertension, suggesting that genetics may play a role in this process. Thus, 
obese African American women and Pima Indians living in the USA display 
milder elevations in biooa pressure (El-Aiat et ai., 2003).
2.2.1. Hypertension
23
Renal
Medullary
Compression
Renal 
Vasodilation
Glomerular
Hypertension
♦ *
t Leptin/POMC
I i?
t  SNS 
' Activity
Tubular NaCl 
Reabsorption,
Volume Expansion
©
Glucose
Intolerance
Arterial
Hypertension
Glomerulosclerosis
|  Lipids
t Glucose
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well as progressive glomerular injury. Adapted from Hall, 2003.
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2.2.2. Diabetes Mellitus
The association between obesity and type 2 diabetes mellitus is well recognized 
(Bjorntorp, 1993b) .The majority of patients with type 2 diabetes are obese 
(Boden, 1996) approximately 85-95% in most population studies (Maggio and Pi- 
Sunyer, 2003). However, only 10% of obese patients are diabetic (cited in Nadler 
et al. 2000). Unfortunately, the increase in adolescent obesity is associated with 
an increase in adolescents with type 2 diabetes. Approximately 85% of children 
diagnosed with type 2 diabetes mellitus in the USA are obese (Mokdad et al., 
2000). Additionally, in a recent study, impaired glucose tolerance / insulin 
resistance was diagnosed in 25% of obese children, 4-10 years old (Sinha et al., 
2002). Serious health consequences may follow diabetes, such as renal failure, 
blindness, and lower-limb amputation, heart disease and stroke.
Obesity not only increases the risk of developing type 2 diabetes mellitus but also 
complicates its management. The presence of obesity exacerbates the metabolic 
abnormalities of type 2 diabetes, including hyperglycaemia, hyperinsulinaemia, 
and dyslipidaemia .Obesity also increases insulin resistance and glucose 
intolerance. Obesity may contribute to excessive morbidity in type 2 diabetes.
The risk of developing hypertension and cardiovascular disease is increased with 
coexistence of obesity and type 2 diabetes (Maggio and Pi-Sunyer, 2003).
The risk of developing diabetes increases by approximately 25 % for each
O 9
additional unit of BMI over 22 kg/m . Thus, when BMI is 35 kg/m the risk of
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developing diabetes will be 38 fold higher than if BMI were <22 (Colditz et al., 
1995). In the USA, the prevalence of type 2 diabetes is more common in African 
Americans than in whites (Ferdinand, 2004). It has been found that weight gain is 
responsible for 27% of new cases of type 2 diabetes in the USA (Ford et al., 
1997). Both cross sectional (Despers et al.,1989; Haffner et al. 1991; Sparrow 
et al., 1986) and longitudinal studies (Chan et al.,1994; Lundgren et al. 1989) 
indicated that central obesity is the main risk factor for type 2 diabetes. 
Epidemiological studies confirm that although obesity is a very important risk 
factor, it may not be enough to produce type 2 diabetes. A genetic susceptibility 
to diabetes may be necessary for obesity to induce overt disease.
2.2.3. Coronary Heart Disease (CHD)
The negative effects of obesity on health and cardiovascular disease are well 
documented (Wikstrand, et al.1993; Lovejoy et al., 1996; Jung, 1997; Lovejoy et 
al., 2001). Body weight, independent of several traditional risks factors, is directly 
related to the development of CHD: a study by Willett et al. (1995, cited in Jung, 
1997) showed that overweight and obese women have an increased risk of CHD 
of 2 and 3.6 fold respectively. Obesity, especially with high abdominal fat, is 
associated with increased morbidity and mortality from CHD (Fujioka et al.,1987) 
.The effect of increased body fatness on cardiovascular function is predictable 
(as shown in figure 2.4). Visceral adipose tissue is the strongest predictor of 
cardiovascular disease in white and African American women (Lovejoy et al.,
2001).The nature of the postulated association between insulin resistance and
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coronary heart disease remains obscure. It has been suggested that tissue 
insulin resistance is the primary initiating defect which leads to compensatory 
hyperinsulinaemia and increased levels of other atherogenic risk factors (Laws 
and Reaven, 1993).
It is well known that obesity is a leading risk factor for chronic arterial 
hypertension and coronary heart disease. Observational studies have shown that 
overweight, obesity and excess abdominal fat are directly related to 
cardiovascular risk factors, including high levels of total cholesterol, LDL- 
cholesterol, triglycerides, blood pressure, fibrinogen and insulin (Haffner et al., 
1991) and low levels of HDL-cholesterol.
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disease.(adapted from Adams and Murphy, 2000).
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2.2.5. Cancer
2.2.5.1. Breast Cancer
Breast cancer is the commonest cancer in women in westernised countries, and 
accounts for about 20% of all female cancers, and it occurs mainly (80%) in 
postmenopausal women (Pharoah et al., 1998). Studies have confirmed that 
obesity has a direct relationship to mortality from breast cancer mainly in 
postmenopausal women (Lew and Garfinkel, 1979; Morimoto et al., 2002; Huang 
et al., 1997). More than 100 epidemiological studies have examined the relation 
of breast cancer with BMI, fat distribution, and weight gain at different ages 
(Morimoto et al, 2002; Huang et al, 1997; Sellers et al., 1992; Friedenreich,
2001).Taken together those studies found that women who were overweight or 
obese had a 30-50% greater risk for postmenopausal breast cancer development 
than leaner women . The International Agency for Research on Cancer estimates 
that 25% of breast cancer cases world wide are due to obesity and a sedentary 
lifestyle (McTiernan, 2003).
2.2.5.2. Colon Cancer
Obese men and women have much higher risk of developing colon cancer. A 
study performed by the Centre for Disease Control and Prevention showed when 
BMI is more than 24 the chances of developing colon cancer doubles and triples 
when the BMI passes 30.
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2.2.5.3. Other kinds of Cancer and Obesity
A study performed in Sweden by Hill and Austin (1996) detected a relationship 
between obesity and cancer risk. The researchers compared the incidence of 
cancer in obese patients with the incidence in the general Swedish population. 
They found 33% more cases of cancer among the obese people than in the 
general population (25% more among men and 37% more among women). The 
obese patients had an increased risk of Hodgkin’s disease among man and 
cancers of the endometrium, kidney, gallbladder, colon, pancreas, bladder, 
cervix, ovary and brain. Figure 2.5 shows the contribution of overweight and 
obesity to mortality from cancer in the USA.
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2.2.6. Gallstones
Gallstones are concretions in the gallbladder or bile duct, composed chiefly of a 
mixture of cholesterol, calcium bilirubinate and calcium carbonate, occasionally 
as a pure stone composed of just one of these substances. The high production 
of cholesterol by the liver results in the bile becoming oversaturated and 
precipitation of cholesterol may occur. Studies suggest that specific dietary 
factors (fatty food and refined sugars) may be responsible. The probability of 
gallstone formation in women increased 2.7 fold in women with severe obesity 
(BMI more than 40) compared with women of BMI less than 24.9, while in men 
the probability increased 2.3 fold for the same categories (Khare et al., 1995).
2.2.7. Osteoarthritis
Overweight or obese people are under a high risk of developing osteoarthritis 
(Cicuttini et al., 1996; Hochberg et al., 1995; Carman et al., 1994; Felson et al., 
1988). Gaining weight is associated with increased mechanical stress of weight 
bearing joints. A study (Marks and Allegrante, 2002) has shown that at least two- 
thirds of osteoarthritis patients were overweight at the time of their surgery, while 
the National Health and Nutrition Examination Survey (NHANES) found that 43% 
of the osteoarthritis subjects were overweight (cited in Marks and Allegrante
2002).
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Studies on animals have shown that obesity affects the respiratory system by 
reducing total lung volume and functional residual capacity. Abdominal obesity 
causes pressure on the diaphragm, decreasing the ability of the lung to expand 
during inspiration, while accumulation of fat on the chest reduces the chest 
cavity.
2.2.9. Sleep Apnoea
Sleep apnoea is characterized by recurrent episodes of cessation of respiratory 
airflow caused by occlusion in the upper airway during sleep, with a consequent 
decrease in oxygen saturation . Many cross-sectional studies have confirmed 
the relation between increased body weight and the risk of sleep apnea (Young 
et al., 2002).Significant sleep apnoea is present in about 40% of obese 
individuals ( Vgontazas et al., 1994 ),and 70% of sleep apnea patients are obese. 
An increase of body weight of 10% in one study was associated with a 6 fold 
increase in the risks of developing of sleep apnoea (Peppard et al., 2000). The 
exact mechanisms underlying the effects of obesity on the risk of sleep apnoea 
are still unclear. It may be related to the effect of fat deposition on airway 
anatomy or changes in upper airway function.
2.2.6. Respiratory system problems
33
2.2.10.1. Menstrual abnormalities and Infertility
Obesity is related to menstrual abnormalities, infertility and, miscarriage. A study 
by Hartz et al., (1979) has shown that obesity was associated with menstrual 
abnormalities including cycles greater than 36 days, irregular cycles, and virile 
hair growth with facial hair. Obesity in pre-menopausal women is associated with 
menstrual abnormalities inducing amenorrhea (Willett et al., 1985). One study, 
found that the risk of subsequent ovulatory infertility was paralleled with 
increasing BMI at the age of 18 years, even in women at BMI levels lower than 
considered to be obese (Rich- Edwards et al., 1994).
2.2.10.2. Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS), is the association of hyperandrogenism with 
chronic anovulation in women without specific underlying diseases of the adrenal 
or pituitary glands. PCOS is associated with obesity, particularly abdominal 
obesity (Franks, 1995). Insulin resistance is considered to be pivotal in the 
expression of PCOS, and is highly associated with abdominal obesity. Direct or 
indirect reduction in insulin concentrations increased ovarian activity (Pettigrew et 
al., 1997). Reduction in weight has been found to significantly improve outcomes 
for obese subjects. In one study of obese infertile women who lost an average
10.2 kg/m2 in a 6 month exercise and diet program the majority resumed 
spontaneous ovulation and achieved pregnancy (Clark et al., 1998).
2.2.10. Obesity and women's reproductive function;
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2.2.10.3. Pregnancy
Studies have reported that obesity during pregnancy is accompanied by 
increased hypertension, gestational diabetes, congenital malformations, and 
morbidity for both the mother and the child (Johnson et al., 1987). Obesity has 
been demonstrated to substantially reduce fertility in the general population and 
to greatly reduce pregnancy rates during ART (Norman and Clark, 1998; Wang et 
al., 2000).
The importance of fat distribution
Many factors are involved in the control of body fat distribution including; gender, 
age , total body fatness and ethnicity (Bjorntorp, 1991). When fat is located 
predominantly in the upper body (the shoulders, face, arms, neck, chest and 
upper portion of the abdomen). This pattern has been termed android, central, 
male, or upper body segment. It resembles the shape of an apple, and is found 
frequently in men (Albright and Stern, 1998). When fat tissue accumulates 
predominantly in the lower body, it is termed gynoid and this pattern is found 
more frequently in women (Albright and Stern, 1998). It is known that women 
have more fat than men even at the same relative body weight index (Sjdstrbm et 
al.,1972; Arner et al., 1991), and this sex difference is caused by greater 
subcutaneous adipose tissue (Kelly et al., 2000). This gender difference is seen 
already in the first year of life and possible even prenatally (Karlberg et al., 1968 
cited in Krotkiewski et al., 1983). Studies have shown that elderly individuals tend
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to accumulate excess abdominal or visceral fat (Brochu et al., 2001; Kohrt et al., 
1993).
The importance of fat distribution has been gaining much attention because of 
the obvious relationship between accumulation of fat in certain area (abdominal 
fat in particular) and elevating the risk of many diseases such as hypertension 
(Cassano et al. ,1990; Folsom et al., 1990; Folsom et al. ,1993; Croft et al.,1993) 
type 2 diabetes (Kissebah and Peiris ,1989; Chan et al., 1994; Carey et al.,
1997; Banerji et al., 1997) cardiovascular disease (Ohlson et al., 1985; Rimm et 
al., 1995; Folsom et al., 1998; Rexrode et al. ,1997; Megnine et al., 1999), stroke 
(Folsom et al., 1990), breast cancer (den Tonkelaar et al., 1992; Kaaks et al., 
1998; Sonnenschein et al., 1999), and risk of death (Kissebah and Krakower 
1994; Lapidus et al.,1984).
The importance of fat distribution was highlighted in the 1940's when Jean 
Vague noticed that subjects with an android body type have an increased risk of 
developing certain diseases compared to gynoid-type subjects (cited in Seidell 
and Flegal, 1997). It was Krotkiewski et al. (1983) who predicted that visceral fat 
may be of particular importance for metabolic aberrations because of its unique 
position and relationship to the portal circulation. Different fat depots vary in their 
responsiveness to hormones that regulate lipolysis (Reynisdottir et al.,1994).
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The high rate of turnover of free fatty acids in the visceral fat depot has an 
important physiological consequence because of the direct link between the 
visceral depot and the liver through the portal vein (Bjorntorp, 1991). Increased 
absolute intra-abdominal fat increased the risk of certain diseases (Kahn, 1993). 
However, there is still considerable controversy regarding the relative importance 
of abdominal fat.
Another important issue is the differences in body composition between different 
ages and between different population groups. Children have more water in their 
bodies, thicker subcutaneous fat, and less minerals and potassium in the fat free 
mass than adults. Hydration status also changes with maturation (Lohman,
1992). South Asians in the UK were found to have more abdominal fat compared 
with Europeans (McKeigue et al., 1991). Asian Indians in the USA were found to 
have high fat relative to body mass index and muscle mass (Banerji et al., 1999). 
These differences were associated with the known complications of obesity, such 
as high blood pressure, higher triglycerides and lower HDL-cholesterol and 
higher fasting and post prandial glucose levels.
Insulin Resistance
Insulin resistance is the impaired ability of insulin endogenous and exogenous to 
control hepatic glucose production and to enhance glucose clearance, mainly into 
skeletal muscle (Walker, 1995). Insulin resistance is the hallmark of the 
metabolic (or dysmetabolic) syndrome. Insulin resistance also impairs other
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biological actions of insulin, including lipid and protein metabolism, vascular 
endothelial function and gene expression. The demands for insulin increase as 
cells become insulin resistant. The body will overcome this by secreting more 
insulin by beta-cells and reduced first- pass clearance of insulin by the liver. This 
increased demand on the pancreatic beta cells may lead to progressive loss of 
beta cell function, secondary to exhaustion of their secretory capacity.
Decreasing insulin sensitivity or insulin resistance also occurs in the normal 
population (Walker, 1995) and is not a prerequisite for the development of type 2 
diabetes (Yki-Jarvinen, 1995; Groop et al., 1993).
The preliminary effect of high insulin production is weight gain, while long 
exposure to high insulin promotes hypertension by impairing sodium balance, 
harm to the kidneys, damage to the vascular system, cardiovascular disease and 
may cause type 2 diabetes (Reaven, 2002; Brett et al., 2000; Suzuki et al.,
2000). Insulin resistance is common in obese patients. Paradoxically, this 
syndrome is also detected in lipodystrophic patients and genetic mouse models 
that completely lack adipose tissue (Moitra et al., 1998; Petersen et al., 2002).
There are many patients with insulin resistance who do not develop diabetes. 
Reasons include PCOS (Franks, 1995), essential hypertension (Cosford, 1999) 
and medications like glucocorticoids (Dessein et al., 2004) which can also, cause 
insulin resistance. The early presence of insulin resistance preceding the onset of
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type 2 diabetes in obese patients is the best predictor of whether or not an 
individual will become diabetic in the future (Warram et al., 1990).
Tumour necrosis factor (TNF) a, which is one of many adipocyte products, may 
play a role as mediator of insulin resistance in infection, tumour cachexia, and 
obesity. Studies in cultured cells have demonstrated that many cytokines can 
modulate glucose transport, and TNF a in particular causes the decreased 
expression of the insulin sensitive glucose transport GLUT4. Using TNFa to treat 
3T3-L1 cells for several days leads to inhibition of GLUT4 transcription and 
expression causing insulin resistance without a depletion of lipid content or a 
change in other fat specific genes such as lipoprotein lipase ( Qi and Pekala, 
2000).
Studies have described two mechanisms to explain the way that TNFa causes 
insulin resistance. Both a defect in the ability of the insulin receptor to 
autophosphorylate and a loss of its ability to phosphorylate its major substrate, 
insulin receptor substrate-1 (IRS-1), on the tyrosine residues has been reported. 
Also, TNFa has the ability to induce serine phosphorylation of IRS-1, which in 
turn inhibits the insulin receptor from phosphorylating this substrate (Qi and 
Pekala, 2000).
There is a strong negative correlation between insulin sensitivity and body 
weight, BMI and waist circumference. The changes in systemic metabolism that
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lead to insulin resistance have been reported to develop in an attempt to prevent 
further weight gain (Eckel, 1992).
The relation between insulin resistance and fat distribution
Many studies have been performed to determine whether overall obesity or 
obesity in a specific depot is a more important determinant of insulin resistance 
(Walker, 1995; Arner, 1997; Ross and Hudson, 1996; Carey et al. 1996) .The 
mechanisms underlying the relationship between visceral adipose tissue and 
subcutaneous adipose tissue and insulin resistance are obscure .
Controversy among scientists about the must important fat depot toward the 
aetiology of insulin resistance syndrome continues. Many researchers report that 
visceral adipose tissue (VAT) is a strong determinant of insulin resistance 
(Brocho et al., 2000; DeNino et al., 2001; Despres et al. ,1989; Ross et al.,2000; 
Arner, 2003; Arner, 2001; Albu et al., 1997; Park et al., 1991; Rendell et al.,
2001; Kissebah and Krakower,1994) .According to the portal theory, free fatty 
acid release by visceral fat is higher than subcutaneous fat, where antilipolytic 
hormones, such as insulin have a more pronounced effect but the lipolytic 
catecholamines have a less pronounced e ffect. Because visceral fat drains into 
the portal vein, rapid visceral lipid metabolism results in the delivery of high free 
fatty acid concentrations to the liver. This in turn leads to stimulation of 
gluconeogenesis, increased triglyceride synthesis and inhibition of insulin
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clearance, which ultimately results in the development of dyslipidaemia, 
hyperglycaemia and hyperinsulinaemia.
The deposition of fat in visceral fat cells is controlled by many factors. The 
androgens and estrogens , beside the peripheral conversion of A4- 
androstenedione to estrone in fat cells are considered to be important factors in 
body fat distribution (Bray , 2003). As fat cells get bigger to reach maturity, their 
secretion of peptides and free fatty acids will increase .These products play a 
major role in insulin resistance and inhibit of the transformation of new 
preadipocytes (Mohammed-Ali et al., 1998; Fried et al., 1998). Danforth has 
hypothesized that failure to differentiate new adipocytes in the subcutaneous 
depots leads to increased fat accumulation in other tissues and fat depots such 
as visceral fat, skeletal muscle, liver and perhaps pancreatic beta cells (Danforth, 
2000). The deposition of fat in non-adipose tissues is an important risk factor of 
insulin resistance and insulin secretory dysfunction. However, the mechanism 
explaining this is still not understood (McGarry and Dobbins, 1999).
Debate continues among studies regarding the importance of visceral fat in men 
and women toward insulin resistance. Corry found that the visceral fat depot in 
women is a constant feature of the development of insulin resistance syndrome, 
while in men this syndrome can be present without visceral fat (Corry, 2001). 
Others reported similar correlation between abdominal fat and insulin resistance 
in men and women (Wagenknecht at al., 2003; Goodpaster et al., 1999).
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Differences among populations in body fat composition may also play an 
important role in insulin resistance. Asian Indians living in the USA, have more fat 
compared with Caucasians with same BMI and have a 60% higher risk of insulin 
resistance than Caucasians (Laws et al., 1994). African Americans and Hispanics 
were found to be more insulin resistant compared with the Caucasians 
(Wagenknecht et al., 2003).The relation between visceral fat and insulin 
resistance syndrome may be weak or less clear in non-Caucasian societies, as 
the accumulation of fat as visceral fat differs among different populations (Perry 
et al., 2000; Gautier et al., 1999). Paradoxically, studies in South Africa have 
shown that black obese women have a higher degree of acquired insulin 
resistance than white females, despite having a smaller amount of visceral fat 
(van der Merwe et al., 2000).
Some researchers have suggested that abdominal subcutaneous adipose tissue 
is largely responsible for the established association between abdominal obesity 
and insulin resistance (Abate et al., 1996; Kelley et al., 2000). It has been 
suggested that a resolution of the above controversy may be achieved by 
subdividing the subcutaneous abdominal fat depot into two layers, using the 
fascia superficialis. The visceral adipose tissue can also be subdivided into two 
layers according to the anatomical characteristics (Kelley et al., 2000).
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Thus the subcutaneous depot has been divided into superficial and deep 
compartments, and the visceral fat divided into intraperitoneal and 
extraperitoneal depots (Cited in Ross, 2002), presuming that adipocytes within 
the deep subcutaneous compartment are more metabolically active compared to 
the superficial adipocytes. Assuming that the liberation of non-esterified fatty 
acids adversely effect insulin action, it follows that the deep compartment would 
be the stronger predictor of insulin resistance (cited in Ross, 2002). This has 
been shown in a cohort of lean and obese men and women. These studies lend 
support to a previous study which reported that posterior subcutaneous fat 
(analogous to deep subcutaneous fat) is associated with insulin resistance 
independent of VAT.
Lipoatrophy, is characterized by a paucity of adipose tissue and interestingly is 
associated with insulin resistant diabetes (Reitman et al., 2000) stressing that 
both increased and decreased white adipose tissue mass can have profound 
effects at extra adipose sites. Therefore understanding, the cellular and 
molecular basis of adipose tissue growth in physiological and pathophysiological 
states is very important.
Due to the interaction among a large number of factors contributing to the 
development of insulin resistance, it is exceedingly unlikely that levels of any one 
factor will enable us to explain the development of insulin resistance. Thus, the
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controversy regarding the identification of all the factors related to the 
development of insulin resistance will continue.
Adipose tissue
Adipose tissue is an areolar tissue specialized as a connective tissue. Its 
traditional function was thought to be a passive depot, storing and releasing lipid 
as triglycerides under the influence of various hormones such as insulin, 
epinephrine, glucagon and Adrenocorticotropic hormone (ACTH). This process is 
a very important part of the energy metabolism (Salans et al., 1973).However this 
definition is restrictive as scientists found that the adipose tissue can play an 
important role as an endocrine and paracrine organ (Mohamed -Ali et al., 
1998;Trayhurn and Beattie 2001). Adipose tissue is found in mammals in two 
different forms, white adipose tissue and brown adipose tissue with different 
physiological roles. The presence, amount and distribution of each vary 
depending upon the species or strain, age, sex, environmental and nutritional 
conditions. However, most adipose tissue in human is white (Cinti, 2002).
Functions and Distribution
Mammalian white adipose tissue, serves three functions : heat insulation, 
mechanical cushion, and most importantly, to store and mobilize energy. The 
adipose cells withdraw fatty acids, glycerol and glucose from the circulation or 
synthesize them from glucose and store them as triglyceride. The glucose mostly 
used to generate the ATP necessary for triglyceride synthesis and esterification.
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Under different circumstances .when cells require energy such as during periods 
of fasting and stress, the adipocytes meet these needs by liberating the free fatty 
acids and glycerol via hydrolyzing the triglyceride, and the cells take on a 
wrinkled appearance. Body heat insulation, is the responsibility of subcutaneous 
adipose tissue. Subcutaneous adipose tissue conducts heat only one third as 
readily as other tissue, and it found exactly below the skin (Summers et al., 2000; 
Runback et al., 2001).
In the infant and young children there is a continuous subcutaneous layer of fat, 
over the whole body, In the adult this thins out in some regions but persists and 
grows thicker in certain sites of predilection. These differ in the two sexes and are 
largely responsible for the characteristic differences in the body form of males 
and females (Lohman, 1992).
Brown adipose tissue is some times mistaken for a type of gland, which it 
resembles more than white adipose tissue. The brown colour of this tissue is 
derived from the cell rich vascularization and densely packed mitochondria. It 
varies in colour from dark red to tan, reflecting lipid content. Brown fat is most 
prominent in newborn animals. In human infants it comprises up to 5% of body 
weight, then diminishes with age to virtually disappear by adulthood. Brown fat is 
of particular importance in neonates, small animals in cold environments, and 
animals that hibernate, because it has the ability to dissipate stored energy as 
heat. In contrast to other cells, including white adipocytes, brown adipocytes 
express mitochondrial uncoupling protein, which gives the mitochondria an ability
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to uncouple oxidative phosphorylation and utilize substrates to generate heat 
rather than ATP. In adult mammals, the main bulk of adipose tissue is a loose 
association of lipid -  filled adipocytes, which are held in a framework of collagen 
fibres. About 60 to 85 % of the weight of white adipose tissue is lipid, with 90 to 
99% triglyceride. Adipose tissue contains stromal- vascular cells including 
fibroblastic connective tissue cells, leukocytes, macrophages, and preadipocytes 
which contribute to structural integrity (Albright and Stern, 1998).
White adipose tissue can be classified into two major divisions, subcutaneous, 
which constitute about 80% of the total body fat and visceral, which constitute 
10% of the total body fat, with other depots such as orbital, retroperitoneal and 
perirenal fat. About 95% of triglycerides in the body, are presented in adipose 
tissue (Arner, 2001).
Expansion of white adipose tissue occurs increasingly after birth as a result of 
both hyperplasia and hypertrophy. The ability of the body to generate new fat 
cells occurs even at a late age (Gregoire et al., 1998) .The increase in the cells 
number occurs primarily by mitotic activity in precursor cells .The developmental 
sequences of adipose tissue in humans is less well defined .In contrast to most 
neonates, the human neonate is born relatively fat .Two periods of hyperplastic 
growth probably occur during the third trimester of pregnancy and just prior to a 
puberty. Contrary to earlier belief, hyperplastic growth can also occur to 
adulthood in both humans and rats (Albright and Stern, 1998).
46
Studies on animals have shown that an exposure to hormones may affect the 
size of adipose cells. Growth hormone (GH), for example is able to reduce 
adipocyte volume and this may be due to a direct action on lipid metabolism by 
decreasing lipogenesis and increasing lipolysis (Lee et al., 1990). Another study 
showed that the chronic administration of GH in vivo reduced both carcass fat 
and the rate of lipid accretion in the carcass (Campbell et al., 1989).
Adipose tissue development
The transition from egg to the determination and conversion of adipocyte 
precursor cells into mature adipocytes occurs in a series of stages as depicted in 
figure 2.6. A single fertilized egg gives rise to nearly 200 different cell types that 
make up the multiple developmental lineages and multicellular organism. The full 
developmental program of preadipose tissue from fertilized egg is unknown. 
However the pluripotent fibroblasts (stem cells) are known to have mesodermal 
origins (Cornelius et al., 1994) and can differentiate into committed 
preadipocytes, cartilage, bone or muscle tissue.
In humans preadipocytes begin to differentiate into adipose tissue during late 
embryonic development, with a majority of the differentiation occurring shortly 
after birth (Burd et al., 1985).This enables the newborn to cope more efficiently 
with intervals between nutrient intake (MacDougald and Lane ,1995). Rat and 
mouse preadipocytes do not begin conversion into adipose tissue until after birth
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(Ailhuad et al., 1992). All species have the ability to differentiate preadipocytes 
throughout their life spans in response to the body’s fat storage demands.
Adipose cells first appears about the fifteenth week of human gestation and 
continue to divide and appear in large numbers until about 23 weeks and then 
divide more slowly through the remainder of gestation. During the first two years 
of life, adipose tissue mass grows by an increase in both size and number, 
initially, by cell enlargement and then after age 6-12 months by an increase in 
both size and number. Cell number increases slowly from two years of age until 
close to the onset of puberty, and during adolescence, there is another sharp 
elevation in cell number that accounts for a spurt in the growth of adipose tissue 
mass. Thereafter the mass of adipose tissue of a non-obese adult maintaining 
constant body weight remains stable as do adipose cell size and number (Salans 
et al., 1973; Bjorntorp , 1974).
The growth and development of adipose tissue in rats is well documented. During 
the first 4 weeks after birth the growth is hyperplastic, then from 4-14 weeks 
adipocyte hyperplasia and hypertrophy occur. After 14 weeks the growth in the 
adipose tissue is predominantly hypertrophic (Ailhaud et al., 1992). Hyperplasia 
and hypertrophy can be altered, when nutritional or other stresses are imposed 
during the preweaning period of growth. Protein restriction during postweaning 
period may severely limit the rate of adipocyte proliferation and differentiation 
(Tulp et al., 1979). Adult obesity is usually, but not always associated with
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hyperplasia and hypertrophy. Thus, adult rodents can increase their cell number 
under some circumstances (Faust et al., 1978).There also appear to be 
circumstances in which the number of adipocytes can increase during adult hood 
in humans (Hirsch, 1976).
Studies on pigs have shown that the increase of weight between first and 
second month of age is due to a sharp increase in cell number, while a 
combination of hypertrophy and hyperplasia is the reason behind weight 
elevation between the second and fifth months , and after five months of age the 
increase of weight is mainly because of hypertrophy .The pigs, like other animals, 
reach a point in their growth at which muscle growth decreases concomitantly 
with an increase in fat deposition (Anderson and Kauffman ,1973).
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Feta! Mesenchyme
Endothelial/Mesenchymal Cords
Primitive Fat Organs
(dense capillaries)
Presumptive Fat Lobules
(identifiable adipocytes, 
nerves, blood, lymph vessels)
40-30 days gestation of pig 
13-20 weeks in humans
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Adipocytes contain small lipid droplets 
Number of lobules increasing
Late Gestation
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Number of small adipocytes increasing 
Lipids droplets still small
Nursing
Most rapid adipose tissue growth
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Preadipocytes proliferate and differentiate
Figure 2.6 Adipose tissue development, adapted from McCusker R. site about 
adipogenesis. on:/classes.aces.uiuc.edu/AnSci312/Adipose/Adipolect.htm.
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Determination is the irreversible commitment of a cell to a pathway of 
differentiation. Determination always precedes differentiation. The process of 
determination causes stability, heritability restrictions in a cells developmental 
potential, which is an important principle of development. However, there are two 
kinds of determination. When the cell holds all the information that it needs, 
determination in this case is called autonomous determination. While when a cell 
depends on instructions from neighbours to direct its differentiation , 
determination is called interactive determination. Specialising and organising 
cells into tissues are the responsibility of the genes, which are present in all cells. 
The fertilized egg, and its early daughter cells are totipotent but, as development 
proceeds, these cells give rise to progressively more specialised cells which have 
a less extensive developmental repertoire but can still develop into multiple cell 
types. In the end, the cells become restricted to their ultimate fate, meaning that 
they become committed to a particular type of differentiation. This commitment or 
determination involves a gradual reduction of development options that ultimately 
renders the cells capable of becoming only a single cell type. This restriction of 
developmental fate occurs gradually and some cells in a lineage become 
committed long after others. For example most adult tissues contain some cells 
that can give rise to various differentiated progeny, and thus by definition are not 
fully committed (Ham and Veomett, 1980; Lodish et al., 1995).
Adipocyte determination
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Determination most likely involves the expression of one or few regulatory genes 
that control the subsequent expression of many other genes in the hierarchy. 
These restrictions of gene expression can be considered to be developmental 
(decisions). These decisions can occur without any apparent change in the 
phenotype of the cells. Therefore one can not establish when a cell has become 
committed until after the determination has occurred (Gregoire et al., 1998).
The ability of PPAR activators to determine cell linage raises other implications 
for lipid differentiation factors in disease processes. Differentiation which has 
gone awry in response to excess lipid derivatives may explain the formation of 
ectopic tissue: cartilage, bone, fat, and even marrow, in atherosclerotic lesion. 
Lipids may also have a role in osteoporosis in which bone stroma is replaced as 
fat. Stromal cells represent about 1% of the cells in the bone marrow. These 
immature mesenchymal precursor cells can differentiate into either adipocytes or 
osteoblastic cells. The decision between the two lineages is regulated, in part by 
PPARy with activation inhibiting osteoblastic in favour of adipogenic 
differentiation of these stromal cells (Parhami et al., 1999). Osteoporosis also 
results from excess osteoclastic resorption relative to osteoblastic formation of 
bone and this is also regulated by lipids. Monocytes may differentiate along the 
macrophage and osteoclast lineage, and this choice is also influenced by PPAR 
activators (Mbalaviele et al., 2000).
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Adipocyte differentiation
Adipocyte differentiation is the process whereby a relatively unspecialised cell 
acquires specialized features of an adipocyte. One of the end results of cellular 
differentiation is the production of cells that are capable of performing a particular 
specialized function .There are two factors affecting differentiation, first the 
communication between individual cells or between cells and second the 
extracellular environment, but these do not reverse a cells commitment. 
Adipocytes or fat cells are fully differentiated cells and are incapable of mitotic 
division. New fat cells, which may develop at any time within connective tissue, 
arise as a result of differentiation of more primitive cells. Although fat cells, before 
they commence to store fat, resemble fibroblasts, it is likely that they arise 
directly from un differentiated mesenchymal cells that are present within the 
body, commonly as pericytes in relation to small blood vessels. Cells usually 
have some differentiated characteristics even though they have not yet become 
fully committed (Gregoire et al., 1998).
The differentiation of a cell is defined by the proteins that it synthesizes and by its 
shape, both characteristics that establish its function. Because cells produce a 
broad range of proteins, not all classes of protein establish whether a cell is 
differentiated. Some proteins are present in all cells , for example mitochondrial 
proteins or glycolytic enzymes , or are common to several cell types, for example
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, the collagens produced by various fibroblasts or the cytokeratins produced by 
various epithelia. The proteins that establish differentiation of a cell type are 
those that enable cell to carry out a unique function. Thus in adipocytes the 
protein enables the cell to produce and store lipid is the one responsible 
differentiation. Cell differentiation arises, in part, from controlling the synthesis of 
these “specialization” proteins (Ham and Veomett, 1980).
The first sign of adipose tissue differentiation is the appearance of lipid droplets 
in the cytoplasm. This is a much easier and more sensitive criterion than 
measuring enzymatic or chemical changes in whole culture, because of 
asynchrony of participating cells and the easy microscopic identification of rare 
cells whose adipose differentiation precedes that of the rest of the population.
It has been detected that a positive feedback loop happens between C/EBP a 
and PPARy which, responsible for maintenance of terminal differentiation 
(Gregoire et al., 1998; Samuelsson et al., 1991; Umek et al., 1991). Any kind of 
molecular disruptions, may effect C/EBPa or PPARy before adipocyte 
differentiation, may stop the process. Cells will not reach maturity or become 
insulin sensitive in term of glucose transport. Many of the genes essential for 
maintenance of a well differentiated adipocyte phenotype require C/EBP a 
including: insulin receptor, insulin receptor substrate-1, fatty acid synthase, fatty 
acid binding protein, and PPARy (Gregoire et al., 1998; Webster et al., 1994;Lin 
and Lane ,1992).
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The morphological changes, that occur during differentiation, organize the cells in 
characteristic shapes. The new shape enables the cell to function effectively. The 
circular shape of the adipocytes enables them to store the maximal limit of lipid. 
However, the extremist case of specialization occurs in the mammalian 
erythrocyte, or red blood cell. The cells lose even their nucleus ,and acquired a 
flattened biconcave membrane-bound bag of haemoglobin (Alberts et al., 1994). 
Extracellular matrix proteins may play a critical role in modulating adipocyte 
differentiation by permitting the morphological changes and adipocyte specific 
gene express ion that associated with differentiation (Gregoire et al., 1998). The 
distinct shapes result from different arrangements of the various cytoskeletal 
components inside the cell, including microtubules, and intermediate filaments. 
The shape of the cell may even control the production of specific proteins. For 
example, milk production mammary epithelial cells can synthesize milk proteins 
only when allowed to assume cuboidal shape, and chondrocytes can produce 
cartilage only when allowed to round up.
Studies showed that the majority of stromal cells present in human adipose 
tissue are able to undergo adipose differentiation under serum-free chemically 
defined culture conditions (Djian et al., 1983). Some differentiated cells may no 
longer be able to under go cell division. Tissues that contain cells in such a 
terminally differentiated state may also contain undifferentiated stem-cell 
populations that are able to divide .These stem cells will subsequently 
differentiate , leading to the terminally differentiated cells for example red blood
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cells , plasma cells,. Other tissues are not capable of producing new cells 
because they consist solely of terminally differentiated cells, for example, 
neurons, cardiac myocytes (Ham and Veomett, 1980).
Studies have shown that the capacity of preadipocytes to differentiate and 
accumulate lipid deteriorates with ageing (Hauner et al., 1989; Kirkland et al., 
1990; Kirkland et al., 1993). Preadipocytes collected from old rats and humans 
accumulate less lipid and have lower lipogenic enzyme activities when exposed 
to variety of conditions that induce differentiation than preadipocytes from 
younger individuals (Kirkland et al., 1993; Hauner et al., 1989). Consistent with 
their declined capacity for differentiation, preadipocytes isolated from old rats 
shown a decreased expression of several differentiation-dependent genes 
compared with preadipocytes cultured from young rats (Kirkland et al.,
1993).These differences were not caused by inherent differences in basal 
expression of these genes in undifferentiated preadipocytes , rather they reflect 
a differences in the extent of expression induced during the differentiation 
process .Thus whereas factors extrinsic to fat tissue (such as d ie t, activity, and 
hormonal milieu ) contribute to declining fat mass during senescence , decreased 
capacity for lipid accumulation also involves age-related processes intrinsic to the 
individual preadipocytes and adipocytes in fat tissue (Djian et al. ,1983).
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Figure 2.7 adipocyte determination and differentiation. Adapted from Gregoire et 
al., 1998.
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The importance of Cell Shape;
The first hallmark of the adipogenesis process is the dramatic alteration in cell 
shape as the cell converts from fibroblastic to spherical shape .These 
morphological modifications are paralleled by changes in the level and type of 
extracellular matrix components and the level of cytoskeletal components 
(Gregoire et al., 1998). More recently, findings indicated that these events are the 
key for regulating adipogenesis as they may promote expression of critical 
adipogenic transcription factors, including CCAAT/enhancer binding protein 
a(C/EBP a) and PPARy. Mediation of the proteolytic degradation of the stromal 
ECM of preadipocytes by the plasminogen cascade is required for cell-shape 
change, adipocyte-specific gene expression, and lipid accumulation (Selvarajan 
et al., 2001).
The alterations in cell shape play a major role during developmental process of 
the cell. Beside its importance in differentiation, cell shape can help to determine 
which proteins are synthesized. As the adipose conversion progresses, the 3T3- 
L1 cells withdraw their processes and change their shape from highly extended 
to nearly spherical (Carraway and Carraway, 1989).
Cell shape is determined by two factors, the first is the interaction with adjacent 
surfaces, either other cells or the extracellular matrix, and second is the 
cytoplasmic framework of fibrillar structures, the cytoskeleton. The cytoskeleton 
is made up of polymers of fibril forming proteins and various accessory proteins 
organized together into microfilaments, intermediate filaments and microtubules.
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The accessory proteins affect filament assembly or link the filaments to one 
another or to other cell components. The cytoskeleton is not a permanent 
structure but changes rapidly in response to cellular events .Indeed the 
characteristic shape and the intermediate filament proteins of epithelial cells can 
change to those of mesenchymal cells during normal development. Various 
external factors, transduced by variety of signalling systems at the surface and 
within cells result in changes in cell shape (Cunningham et al., 1987).
Origin o f 3T3-L cells
The in vivo study of preadipocyte differentiation is difficult. Fat tissue within 
animals consists of approximately one third adipocytes, while in humans it is 
about 50% (Cornelius et al., 1994). The remaining percentages of human and 
animals fat tissue is a combination of small blood vessels, nerve tissue, 
fibroblasts and preadipocytes in various stages of development (Geloen et al.,
1989). It is difficult to distinguish preadipocytes from fibroblasts and the inability 
to align preadipocytes at similar developmental stages confounds details in vivo 
studies. Despite these difficulties, preadipocyte primary culture has been used 
(Lodish et al.,1995) however, such primary cultures present a number of 
problems. First, the contamination of preadipocytes with other kinds of cells 
increases the difficulty of isolating pure preadipocytes. Second, due to the low 
percentage of preadipocytes of total adipose tissue, a large amount of adipose 
tissue is needed in order to get enough preadipocytes. Furthermore, primary 
cultures have a limited life span in culture (Ntambi and Young-Cheul, 2000).
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Therefore, the molecular control of adipogenesis has largely been studied by 
using in vitro models .There are advantages and disadvantages to the use of a 
cell line to study preadipocyte differentiation. A cell line derived from cloning is a 
homogenous population of cells that are all at the same stage of differentiation. 
This allows for definitive responses to treatments. The ability to passage these 
cells has added another important facility to the study of adipogenesis by 
providing a stable source of preadipocytes .The disadvantage is that the 
molecular events that constitute adipogenesis in a cell line are not necessarily 
the same as those in a human preadipocyte. Furthermore, the ability of a 
preadipocyte cell line to differentiate often falls with increasing passage number 
(Ntambi and Young-Cheul, 2000).
Cells of clonal lines can be classified into three groups. First are the totipotent 
embryonic stem cells (or ES cells). Second, the multipotent or pluripotent stem 
cells following myogenic, chondrogenic or adipogenic pathways (C1, TA1, 30A5, 
azaCyd, 10T1/2, Bal/c 3T3, 1246, RCJ3.1 and CHEF/18 fibroblasts). The third 
class, is the unipotent preadipocytes (3T3-L1, 3T3-F422A, 1246, Ob1771, TA1 
and 30 A5), and these cell lines have undergone determination to the adipose 
linage, and can either remain as preadipocytes or undergo conversion to adipose 
tissue (Ailhaud, 1997). The models most frequently used for studies of adipocyte 
development are subclones of the 3T3 cell line and the ob 17 cell line (Kim and 
Moustaid-Moussa, 2000).These clonal cells possess the ability to differentiate 
into adipose cells in the presence of adipogenic factors after becoming confluent
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and reaching a state of growth arrest. On the basis of studies on these cell lines 
two stages have been identified during the adipose differentiation process. The 
first step is the commitment of the cells to differentiation process, which requires 
growth arrest and is characterized by the expression of early markers of 
differentiation such as lipoprotein lipase (Ailhaud,1992; Amri et al., 1986).The 
second step represents the terminal differentiation of the cells, including the 
acquisition of the adipocyte phenotype .
The 3T3-L1 and 3T3 -F422A culture lines which originated from disaggregated 
Swiss 3T3 mouse embryos are the most commonly used culture models. The 
3T3 line was evolved from the disaggregated cells of late foetuses of the mouse. 
It is an excellent model system for studying the behaviour of fibroblasts and 
molecular events responsible for the differentiation of preadipocytes into 
adipocytes .These cells undergo differentiation, when subjected to a 
differentiation regimen consisting of insulin, dexamethasone, and isobutyl- 
methylxanthine (Wang et al., 1992).
In normal development, preadipose cells lose their ability to grow when they 
mature; but if they are kept in the growing state under culture conditions there is 
no obvious reason why they should not become established cell lines, like other 
mesenchymal cell types of rodents. Though, under certain conditions, the 
appearance of 3T3 cells may resemble that of endothelial cells, they are 
fibroblasts by functional criteria. When the growth of 3T3 cells is arrested, a
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certain proportion will convert to adipose cells. This is true for each of a 
considerable number of randomly chosen clones isolated from 3T3 stock stored 
frozen for over a decade (Green and Kehinde, 1974).
Endocrine and Paracrine effect of the adipocyte
Mature adipocytes, the main cellular component of white adipose tissue, are 
uniquely equipped to function in energy storage and balance under tight 
hormonal control. However, with the realization that adipocytes secrete factors 
known to play a role in, insulin sensitivity, immunological responses, vascular 
diseases, and appetite regulation, a much more complex and dynamic role of 
white adipose tissue has emerged. In addition to proteins involved in lipid and 
lipoprotein metabolism, cytokines, and growth factors, adipocytes also synthesize 
factors involved in the regulation of food intake and energy homeostasis. 
Adipocyte derived factors include leptin, adipsin, acylation stimulating protein, 
agouti, angiotensinogen, prostaglandins, adiponectin, resistin, TNFa, 
macrophage migration inhibitory factor, and PPARy (Kim and Moustaid-Moussa 
2000; Rosen et al., 2000; Fruhbeck et al., 2001) (See Figure 2.8).
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Figure 2.8 Adipocyte products, adapted from Fruhbeck et al., 2001
63
Alkaline phosphatase is an enzyme made in many tissues. The enzyme present 
in all tissues of the body especially at or in the cell membranes, and it exist at 
high concentrations in intestinal epithelium, kidney tubules, bone (osteoblasts), 
liver, and placenta. ALP, like many other isoenzymes works in alkaline 
environment, and it catalyses the hydrolysis of phosphatase esters releasing an 
alcohol and inorganic phosphate. As the enzyme has low specificity, it can 
hydrolyse a wide range of substrates. Although, the precise role of ALP is not yet 
clear, it appears that the enzyme is associated with lipid transport in the intestine 
and with the calcification process in bone (McComb et al., 1979).
The optimum activity of alkaline phosphatase is at about pH 10 in vitro thus the 
enzyme itself is inactive in the blood. Alkaline phosphatase acts by hydrolysing 
phosphorus (an acidic mineral) bonds, creating an alkaline hither main 
importance of measuring alkaline phosphatase is to check the possibility of bone 
or liver disease. Since the mucosal cells that line the bile system of the liver are 
the source of alkaline phosphatase, the free flow of bile through the liver and 
down into the biliary duct and gallbladder are responsible for determining the 
enzyme level in the blood.
It was thought before that ALP reaching the liver from other tissues (especially 
bone) was excreted into the bile and that the elevated serum enzyme activity 
found in the hepatobiliary disease was the result of failure to excrete the enzyme 
through the bile. It is now clear that the liver secretes more ALP in the case of
Alkaline Phosphatase:
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hepatobiliary disease. Thus, blocking the bile duct with stone for example enough 
to increase the level of the enzyme in the blood serum more than three fold. 
When the liver, bile ducts or gallbladder system are not functioning properly or 
are blocked, this enzyme is not excreted through the bile and alkaline 
phosphatase is released into the blood stream. Thus the serum alkaline 
phosphatase is a measure of integrity of the hepatobiliary system and the flow 
of bile into the small intestine (Eliakim et al., 1991).
Temporary increase of the enzyme is found during bone fracture healing, growing 
children, and third trimester of pregnancy (McComb et al., 1979).
The relationship of alkalinity to bone development warrants further discussion 
because its plays a major role in the prevention and reversal of osteoporosis. 
Calcium comes out of solution and crystallizes in an alkaline environment, but is 
dissolved in an acidic environment. The osteoblasts by creating a local 
environment of alkalinity via alkaline phosphatase help build bone Its also implies 
that in order to slow bone loss, one can not be in an acidic state Studies have 
shown that giving potassium bicarbonate is just as effective as calcium in 
correcting osteoporosis. Therefore in an acidic state, the body will compensate 
by increasing the bone alkaline phosphatase levels. The optimal range for 
alkaline phosphatase depends on the age .A growing adolescent will have a 
much higher alkaline phosphatase level than a full grown adult because her/his 
osteoblasts are laying down bone very rapidly (see table 2.4).
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Adults U/l
Men (n=221) 40-129
Women(n=229) 35-104
Children U/l
aged 1 day <250
aged 2-5 days <231
aged 6 days to 6 months <449
aged 7months to 1year <462
aged 1year to 3 years <281
aged 4 to 6years <269
aged 7 to 12 years <300
aged 13-17 years(males) <390
aged 13-17 years(females) <187
Table 2.4 shows ALP normal levels in men, women, and children.
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Alkaline phosphatase (ALP) is a zinc and magnesium -containing metalloenzyme 
(EC 3.1.3.1) that hydrolyzes phosphate ester with a high pH optimum. It is found 
in most species from bacteria to humans and also as free enzyme in natural 
waters and sediments. In mammals, it is a glycoprotein attached to the 
membrane by a glycosylphosphatidylinositol (GPI) anchor (McComb et al., 1979).
In mammals, there are four different ALP isozymes are currently known, each 
encoded by at least one separate gene. Three of the four are tissue specific 
alkaline phosphatase: the placenta, the placenta like germ cells, and intestinal 
isozymes .The fourth isozymes, known as liver/bone /kidney isozyme, is tissue 
non-specific alkaline phosphatase and has physical and biochemical properties 
that clearly distinguish it from the other ALP isozymes (Moss, 1982; Harris,
1989).
Intestinal alkaline phosphatase is a late development in the alkaline phosphatase 
gene family, appearing first in mammals and before the appearance of placental 
ALP in primates. All these intestinal ALPs are compact genes contained within 5­
6 kb. There are fetal and adult forms of human intestinal ALP (Eliakim et al.,
1991, Young et al. 1981).
Most species express just a single intestinal ALP. The multiple forms of mRNAs 
encoding human Intestinal ALP are due to differences in polyadenylation, and
Alkaline phosphatase isozymes
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only one protein is produced .At least two protein isozymes have been reported 
in two species, the cow and the rat .The rat intestine produces two isozymes of 
intestinal ALP , but unlike the near identity of isozymes in the other species these 
share only 79% identical amino acids (Young et al., 1981).
Placental alkaline phosphatase (EC3.1.3.1) is a dimeric sialoprotein that is 
expressed in the membrane of the syncytiotrophoblast of the human placenta 
During pregnancy, Placental ALPs is synthesized after the 12th week and is shed 
into the maternal circulation. It is serum concentration is correlated with its 
placenta growth, increases as pregnancy proceeds and reaches its maximum at 
the last three months. Placental ALPs activity in plasma may be used as an 
indicator of placental function (Fishman and Sie.,1971, McComb et al., 1979)..
Role of alkaline phosphatase
Up to date there is little biochemical evidence for alkaline phosphatase function 
.except its role in bone mineralization(via its role in the metabolism of calcium 
phosphates) (Yoon et al.,1989;Beertsen and van den Bos 1992;Fedde et 
al.,1999) and dephosphorylation of adenosine nucleotides (Gallo et al.,1997).The 
ALPs have been postulated to be involved in a range of other processes , 
including cell adhesion, vitamin B transport, and cell signalling (Rindi et 
al.,1995;Muler et al.,1991,Hui et al.,1993).On the other hand humans with 
mutations in the tissue non specific ALP isozyme have defective bone 
mineralization , infantile hypophosphatasia ( Henthorn et al.,1992).
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ALP is a marker of osteoblast linage, and hypophosphatasia, a recessive human 
disease with multiple bone disorders, has been linked to mutations in ALPL, the 
tissue non specific ALP (Henthorn et al., 1992).
The tubules are sites for deposits of calcium and magnesium phosphates in the 
form of luminal concretion bodies, orspherites (Wessing and Eichelberg, 1978). 
These bodies have traditionally been considered to be sites of storage extraction 
of phosphates of calcium, magnesium, and other metals. As these spherites pack 
into the initial segments of the anterior tubules, it is possible that the deposits are 
laid down in the initial segment and then pass though the tubule to be excreted in 
the urine. Alkaline phosphatase on the apical surface of the lower tubule might 
allow for the selective reclamation of calcium when needed. This might explain 
the semilethal nature of the mutations; the severity of the disruption of calcium 
metabolism might depend on the nature of the diet.
Alkaline phosphatase activities in the vertebrate brain are generally lower than 
those in the liver and kidney (McComb et al., 1979). However, in the neuronal 
tissue, intense alkaline phosphatase activity has been located in the neuronal cell 
bodies and processes in some parts of central (CNS) and peripheral nervous 
systems (PNS) of many animals such as mouse and rat (Sood and Mulchandani, 
1977). The enzyme has been localized on the outer surface of plasma 
membranes of nerve cell bodies and dendrites (Mori and Nagano, 1985). It has 
been shown that alkaline phosphatase is associated with synaptic vesicles
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isolated from bovine cerebral cortex (Zisapel and Haklal, 1980). It has suggested 
that ALP has a function related to particular features of the reactive neurons. All 
these facts shown that ALP may play some role in transmembrane transport and 
in cell differentiation in the nervous tissue (Mahmood et al., 1992). .
Inhibition of alkaline phosphatase
Inhibitors can be divide into two classes, reversible and irreversible types. 
Reversible inhibition implies that the activity of the enzyme is fully restored when 
the inhibitor is removed from the system in which the enzyme acts by some 
physical separative process, such as dialysis, gel filtration, or chromatography.
An irreversible inhibitor, on the other hand, combines covalently with the enzyme 
so that physical methods are ineffective in separating the two.
Competitive inhibition by metal ions can arise when two metal ions compete for 
the same binding site on the enzyme. Thus Ca+2 is an inhibitor for some enzymes 
that depend on Mg+2 activation (Stryer 1980). Whilst divalent ions like Mg+2, Co+2, 
Mn+2 are activators of ALP (McComb et al., 1979).
Levamisole is a strong non-competitive inhibitor of liver, bone, kidney alkaline 
phosphatase whilst having little effect on the intestinal or placental form (van 
Belle, 1976). This inhibitor has been used over a wide range of concentrations to 
inhibit ALP. Thus, 5mM levamisole causes maximum inhibition of ALP in human 
serum (Chan and Kellen, 1975), whilst ALP purified from human bone can be 
inhibited by concentrations between 1-100uM (van Belle, 1976), 100uM causing
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nearly 100% inhibition. Levamisole however, also has many other effects 
including immunomodulatory and anthelminthic properties (Amery and 
Bruynseels, 1992) and can act as a nicotinic and adrenergic receptor agonist 
(Hsu, 1980). The related compound, L-P-Bromotetramisole has been found to be 
more potent than levamisole as an inhibitor of alkaline phosphatase (Brogers et 
al., 1975). The stereospecificities of these alkaline phosphatase inhibitors have 
been demonstrated biochemically as well as cytochemically in a variety of tissues 
and species. It has been suggested that both these compounds inhibit ALP 
activity by blocking dephosphorylation of the phosphoenzyme (van Belle, 1976). 
Phenylalanine has been used to inhibit placental and intestinal alkaline 
phosphatase enzyme, the inhibition being approximately 80%, whilst there is little 
effect on the liver or bone enzymes (Fishman et al., 1963). L-homoarginine is a 
particularly powerful inhibitor of the bone and liver enzymes whilst the intestinal 
and placental enzymes are less effected (Fishman and Sie, 1970).
It has been shown that Phe Gly Gly inhibits intestinal ALP, but not tissue non­
specific ALP. Intestinal ALP is well known as a tissue specific alkaline 
phosphatase (Doellgadt and Fishman, 1977). Histidine, has also been used as a 
tissue non-specific alkaline phosphatase inhibitor (Fishman and Sie, 1971). The 
mechanism by which these amino acids block ALP activity is uncertain, although 
it has been suggested that like levamisole the Phe containing inhibitors may 
block dephosphorylation of the enzyme (van Belle, 1976).
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Alkaline phosphatase activity has been inhibited by okadaic acid. Kinetic analysis 
has demonstrated that okadaic acid acts as a non-competitive inhibitor of alkaline 
phosphatase from E.coli. The same inhibition pattern was obtained for the human 
placental and the calf intestinal enzyme (Mestrovic and Pavela-Vrancic 2003).
Aims of study
The main aims of this study were to:
1. Determine whether ALP is expressed in 3T3-L1 cells and human 
preadipocytes
2. Determine whether ALP is involved in the adipogenic process by use of ALP 
inhibitors
3. Determine whether ethnic differences exist in adipogenesis in white and black 
South African females
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CHAPTER THREE
MATERIALS AND METHODS
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3.1. Murine 3T3-L1 Cell Culture Work
3.1.1. Preparation o f DMEM and Trypsin Solution
The substances in table 3-1 were mixed together. The pH of the solution should 
be 7.1-7.2. The medium was filter-sterilised before use using a 0.22micron sterile 
syringe filter and was stored at 4°C until use.
Table 3-1: Murine 3T3-L1 Culture Medium (DMEM)
Substances Amount added
Dulbecco’s Modified Eagle Medium 
(Gibco Invitrogen Corporation) 1 35g
Sodium bicarbonate 
(Merck) 0.37g
Foetal Bovine Serum 
(Gibco BRL) 10.0ml
Penicilin (10000U/ml)/Streptomycin (10000ug/ml) 
(BioWhittaker) 1.0ml
Sodium pyruvate (100mM) 
(Gibco Invitrogn Corporation) 1.0ml
L-Glutamine (200mM)
(Gibco Invitrogen Corporation 1.0ml
Distilled water
87ml
Total Volume 100ml
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Trypsin solution: This was used for passaging the 3T3-L1 cells. A 10x trypsin 
stock solution (Sigma) was diluted 10 fold with phosphate buffered saline (PBS), 
pH 7.2 . Trypsin was then filter sterilised and allocated in 1ml aliquots to cryo- 
tubes and frozen at -20  °C, until needed.
3.1.2. Transformation Medium
Transformation medium was used for initiating the conversion of the 3T3-L1 
cells into adipocytes. It was prepared using the DM EM described in table 3.1 
This was supplemented with the following;
3- lsobutyl-1-methylxanthine (IBMX) (Sigma)
A 25 mg aliquot of IBMX was dissolved in 1ml of warm methanol. From this,
0.1ml was added to every 50 ml of DMEM to give a final concentration of 0.5mM. 
Dexamethasone (Sigma)
A 1mg measure of dexamethasone was dissolved in 1 ml 99% ethanol (BDH), 
and then this was diluted to 20ml with PBS. A 0.1ml aliquot of this solution was 
added to every 50ml of DMEM to give a final concentration of 0.22uM.
Insulin (U100 Actrapid insulin, Novo-Nordisk)
A 0.13ml aliquot of insulin was added to every 50ml of DMEM to give a final 
concentration of 1.7uM.
After the addition of all 3 reagents to the DMEM the medium was filter 
sterilised and used immediately.
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3.1.3. Freezing and Thawing Cells
To create a stock of frozen 3T3 L-1 cells, the confluent cells (grown in 25 
cm2 flasks) were rinsed with sterile PBS and detached by incubating with 1 ml of 
trypsin for 5-10 minutes at 37 °C. The reaction of trypsin was stopped with DMEM 
containing 10% foetal bovine serum (FBS), and the cell suspension was 
centrifuged at 4000 g for 3 minutes . The supernatant was discarded and the cell 
pellet was resuspended with 2ml of freezing medium , which consisted of the 
DMEM described in table 3.1 supplemented with 10% dimethyl sulphoxide 
(DMSO; Sigma). This solution was then dispensed into cryo-vials, 1ml per tube 
and left overnight in a polystyrene container at -70 °C. The following day the vials 
were transferred to liquid nitrigen.
Cells were re-cultured by removing vials from liquid nitrogen storage and 
placing in a 37 °C water bath. Cells thawed quickly with shaking and were 
transferred to a 25cm2 tissue culture flask containig 5ml of DMEM supplemented 
with 20% FBS. Cells were incubated overnight in a 37 °C incubator in a 95% air 
5% carbon dioxide atmosphere. Cells were checked for growth and medium 
replaced with fresh medium. If cells were seen to be growing well DMEM-20% 
FBS was replaced with DMEM containing 10% FBS after 3-4 days ie medium in 
table 3.1.
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3.1.4. Culturing and Transforming the 3T3-L1 Cells
Transformation medium was added to cells in 25cm2 flasks once they 
were confluent .Only cells that had been passaged less than 10 times were used 
for transformation .After 3 days incubation with transformation medium , the 
medium was replaced with DMEM containing all ingredients in table 3.1, plus 
1.7uM insulin. Cells were maintained for a further 3 days in this medium after 
which it was replaced with normal DMEM (table 3.1). Medium was then changed 
every third day.
3.1.5. Alkaline Phosphatase Inhibitors Used with 3T3-L1 Cells
Inhibitors of ALP activity were added to 3T3-L1 cells at the same time as 
adipogenesis was initiated with transformation medium. Cells were cultured up to 
11 days in the presence of these inhibitors and medium was changed every third 
day (see 3.1.4). ALP activity and adipogenesis were measured at base line and 
3, 7, and 11 days after addition of transformation medium. With the inhibitor Phy 
Gly Gly, these variables were measured only on day zero, 7, and 11. The 
inhibitors used were:
Levamisole (Sigma)
Levamisole. (0.048g) was dissolved in 2ml PBS and shook until solution was 
clear. Solution was filter sterilized using a 0.22 micron filter, then 100ul was 
allocated in each 5ml of tissue culture medium, to give a final concentration of 
2.0 mM.
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L-phenylalanyl-glycyl-glycine (Phe-Gly-Gly) (Sigma)
A 0.056 g measure of Phe-Gly-Gly was dissolved in 20ml of culture medium, and 
shook in order to ensure that it was fully dissolved. The medium was then filter 
sterilized, and 5ml allocated into 25cm2 culture flasks containing confluent 3T3- 
L1 cells. The final concentration was 20 mM.
Histidine (Merck)
Histidine (0.465g) was dissolved in 60ml of culture medium and shook , then the 
medium was filter sterilized and 5ml allocated into 25 cm2 culture flasks 
containing confluent 3T3-L1 cells .The final concentration was 50 mM.
The concentrations of the three inhibitors, used were taken from the literature 
and were confirmed by comparing the effects of different concentrations of each 
inhibitor on ALP activity or level of adipogenesis. The same concentrations were 
used for both 3T3-L1 cells and human preadipocytes. The concentrations used 
were: levamisole 2.0 mM (van Belle, 1977, Price, 1993); histidine, 50 mM 
(Fishman and Sie, 1971); Phy Gly Gly, 20 mM (Doellgast and Fishman ,1977).. 
For levamisole, ALP activity in 3T3 -L1 cells was measured after 7 days of 
transformation (see section 3.3, and 3.4) over a range of concentrations (0.5 mM, 
1 mM and 2 mM) on two separate occasions. For histidine, adipogenesis in 3T3- 
L1 cells was assessed visually after 7 days of treatment with 25 mM, 50 mM and 
100 mM of histidine. Phe.Gly.Gly was assessed in a similar manner to histidine 
using concentrations of 10, 20, 40 and 80mM.
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3.2. Measurement of Adipoqenesis
Adipogenesis was measured using the oil red O technique. This technique 
depends on the ability of the lipid droplets in the mature adipocyte to collect the 
red stain. Oil red O (Sigma) was prepared (Ramirez-Zacarias et al., 1980) by 
dissolving 420 mg oil red O in 120 ml of absolute Isopropyl alcohol (BDH). The 
solution was then gently shaken at room temperature overnight .The solution was 
then filtered twice through a Whatman filter paper then 90 ml of distilled water 
was added and working solution was left overnight at 4°C.
Intracytoplasmic lipids were quantitated according to the method of 
Ramirez-Zacarias et al. The 3T3-L1 cells were fixed by addition of 
glutaraldehyde to a final concentration of 3% for 2 hours. Fixation solution was 
then replaced by 500pl of 60% isopropyl alcohol. After 5 min, isopropyl alcohol 
was evaporated and preadipocytes were stained by complete immersion in a 
working solution of 300pl oil red O for 2 hours. The stain solution was removed 
and cells rinsed in 500pl of 60% isopropyl alcohol for 5 s. The dye was extracted 
from the cells by adding 700pl of 60% isopropyl alcohol and shaking for 2 h. The 
extracted dye was quantitated spectrophotometrically by measurng the 
absorbance at 510 nm.
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3.3. Extraction of Alkaline Phosphatase from Cells
Table 3-2. Alkaline Phosphatase Ceil Extraction Solution
Substance Amount used
Tris-HCL (Sigma) 157.6mg
Triton x-100 (Sigma) 1ml
Phenylmethylsulphonyl fluoride (Sigma) 35mg
Distilled Water 100ml
The solution was pH’ed to pH 7.2. Extraction solution was aliquotted in to 
Eppendorf tubes (1ml per tube) and kept at -20  °C.
Cell extracts of 3T3-L1s were isolated at baseline and 3, 7 and 11 days 
after initiation of adipogenesis using the method of Merchant-Larios et al. 
(Merchant-Larios et al., 1985).Thus, tissue culture medium was removed from 
the cells and 0.5 ml of ice cold extraction solution was added. The flasks were 
shaken to detach the cells and the suspension transferred to an Eppendorf tube 
and centrifuged for 10 minutes at 15,000 g. The supernatant was removed and 
immediately analysed for alkaline phosphatase activity using an automated 
colorimetric assay (see section 3.4). The protein content of the supernatant was 
analysed using the Bradford method (Bradford, 1976) see section 3.5. Alkaline 
phosphatase activity was calculated as ml) of activity per mg protein.
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3.4. Measurment of alkaline phosphatase activity
Alkaline phosphatase activity was measured in the Chemical Pathology 
routine laboratory at the Johannesburg General Hospital, Parktown using a 
commercial kit (Roche) on an autoanalyser (Modular, from Roche). The assay 
was performed by a medical technologist. Each assay run contains internal 
control samples and data was only accepted if controls gave readings within the 
range specified by the kit manufacturers (Roche). Alkaline phosphatase was 
measured in human serum samples and cell extracts (see section 3.3). Alkaline 
phosphatase extraction solution was analysed using this assay method and gave 
a zero reading on the autoanalyser. The extraction solution was also shown not 
to interfere with the assay by diluting human serum with the extraction solution 
and then measuring alkaline phosphatase activity on the autoanalyser.
3.5. Measurment of cell protein
The protein content of 3T3-L1 and human preadipocyte cell extracts was 
measured using the Bradford method (1975). The protein reagent was prepared 
by dissolving 100mg ofG-250 (Sigma) in 100ml of 85% phosphoric acid (Merck) 
then 50ml of 95% ethanol (Merck) was added to the mixture and 850ml of 
distilled water was also added . The solution was shaken unil the G-250 was 
completely dissolved.
The albumin standard was prepared by dissolving 1 mg of albumin 
(Sigma) in 1ml distilled water. The albumin standard curve was prepar from this 
stock solution as described in table 3.3.
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Table 3- 3. Albumin standard curve for Bradford protein assay
Volume of albumin stock (ul) Volume of distilled water (ul)
0 1000
20 920
40 960
60 940
80 920
100 900
120 880
The above standards were vortexed and then 300ul was taken from each 
and mixed with 2.7ml from the protein reagent. At the same time 50ul from each 
sample was added to 950ul of distilled water and vortexed .Then 300ul was taken 
and added to 2.7ml of protein reagent. All samples were vortexed and then 
absorbance measured in disposable cuvettes.
3.6. Culture of human preadipocytes 
3.6.1.Subjects
3.6.2. Breast Reduction Subjects
Human adipose tissue samples were obtained from the mammary adipose 
tissue of 15 white women of mean BMI 24.7± 1.3 (range 22.2-26.1) and mean 
age 43.0±4.6 (range 35-51). Tissue was also obtained from 13 black females of
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mean BMI 25.1±1.6 (range 22.0-26.7) and mean age 45.7±5.0 (range 38-55). 
Subject details are given in table 1 of Appendix 1. All subjects were undergoing 
elective surgical mammary gland reduction. All subjects were healthy. All women 
were free of disorders of carbohydrate and lipid metabolism, as assessed by 
history and clinical examination. Ethical approval for use of the adipose tissue 
was obtained from the University of Witwatersrand, Faculty of Health Sciences 
Human Ethics Committee. Informed consent was obtained from each patient 
before surgical intervention. Adipose tissue was processed immediately after 
removal, and was transferred to the laboratory in sterile Hanks balanced salt 
solution (Gibco) supplemented with 25mM HEPES (Sigma), 100 U/ml penicillin, 
100ug/ml streptomycin (BioWhittaker), 3% bovine serum albumine (Sigma) and 
pH of 7.2. This medium is called “human adipocyte isolation medium".
3.6.3. Abdominal Subcutaneous Adipose Tissue Subjects
Human abdominal subcutaneous tissues samples were obtained from 13 
black women of mean BMI 38.±7.4 (range 29.3-53.5), and mean age 46.5 ± 6.5 
( range 35-58). Subject details are given in table 2 of Appendix 1. All women 
were free from diseases, and disorders of carbohydrate and lipid metabolism, as 
assessed by history and clinical examination. These subjects had been 
volunteers in previous studies and fasting blood glucose levels had shown them 
to be non-diabetic. Ethical approval for use of the adipose tissue was obtained 
from the University of Witwatersrand, Faculty of Health Sciences Human Ethics 
Committee. Informed consent was obtained from each volunteer.
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A small incision biopsy was performed under local anaesthesia (2% 
lignocaine). The skin incision was approximately 2cm in length and the 
procedure performed in theatre under sterile conditions and with the availability of 
cauterisation to control small bleeding points. A total of 5-1 Og of subcutaneous 
fat was removed from the torso of each patient from a site to one side of the 
umbilicus and placed in sterile isolation medium. As described in section 3.6.2. 
Preadipocyte isolated was peformed immediately.
3.6.4. Isolation of Preadipocytes and Mature Adipocytes from Human 
Subcutaneous Abdominal and Mammary Gland Adipose Tissue
Human fat tissue was collected from the theatre in sterile human adipocyte 
isolation medium. After excision of blood vessels, adipose tissue was minced into 
small pieces using sterile scissors, then the sample was washed with isolation 
medium and centrifuged for 5 minutes at 380g. Tissue was then decanted into 
isolation medium (0.7g tissue per ml medium) supplemented with 0.75mg/ml 
collagenase (Roche) and digested 1 hour at 37 centigrade with constant shaking. 
Suspended cells were then filtered through a 250micron metal filter and the 
product spun for 10 minutes at 380g. This gives rise to a pellet of stromavascular 
cells containing the preadipocytes and a layer of mature adipocytes which float 
on top of the medium due to their high fat content. The mature adipocytes were 
taken and frozen in liquid nitrogen, and the solution over the stromavscular pellet 
thrown away,while the pellet was resuspended in 100ml of red cell lysis buffer 
(0.154M ammonium chloride [Univar], 10mM potassium bicarbonate [Merck],
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0.1m M EDTA [Sigma] and 10% fetal bovine serum [Gibco]) and allowed to settle 
for 10 minutes at room temperature followed by 10 minutes centrifugation at 
380g. The cell pellet was resuspended in human preadipocyte tissue culture 
medium. This medium was DMEM-F12 medium (BioWhittaker) containing 15mM 
HEPES and 2mM glutamine, supplemented with 10% fetal bovine serum (Gibco) 
and 100 U/ml penicillin, 100ug/ml streptomycin (BioWhittaker). The cells were 
then filtered through a 20micron nylon mesh and aliquotted into 6-well tissue 
culture plates (Nunc). The preadipocytes were then cultured overnight and the 
next day were washed using DMEM-F12 medium.The medium was changed 
every third day until cells were confluent. At this point, adipogeness was initiated 
by adding the transformation medium. This medium is the same as the human 
preadipocyte tissue culture medium described above with these additions: 
Hydrocortisone (Sigma)
1mg was dissolved in 0.5ml of absolute ethanol and 0.5ml chloroform and 90ul of 
this mixture was added to 3.8ml of PBS. From this solution 100ul was added to 
50ml of DMEM-F12 medium , to give a final concentration of 100 nM 
3, 3, 5-Triiodo-1-thyronine (Sigma)
1 mg was dissolved in 1ml of 1M sodium hydroxide. From this solution 100ul was 
taken and added to 1ml PBS. Then, 14ul was taken from this solution and added 
to 1ml PBS. Finally, 25ul was taken from this solution and added to 50ml DMEM- 
F12, to give a final concentration 1 nM.
IBMX (Sigma)
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25 mg was weighed and dissolved in 1ml of warm methanol, then 110pl was 
taken from this solution and added to 50ml of DMEM-F12, to give a final 
concentration of 0.5 mM.
Insulin (U100 Actrapid insulin, Novo-Nordisk)
A 0.13ml aliquot of insulin was added to every 50ml of DMEM to give a final 
concentration of 1.7pM.
3.6.5 Inh ib itor studies on human preadipocytes
Adipogenesis and ALP activity were measured on day zero and following 12 days 
of cell growth in transformation medium. Adipogenesis and ALP activity were 
measured using the same techniques previously described for the 3T3 L1 cells 
(see sections 3.2, 3.3 and 3.4). Inhibitors were added to the cells on day zero 
through to day 12, with medium changed every three days. ALP activity was also 
measured in human preadipocyte cell extracts in the presence and absence of 
levamisole. This was performed on 5 different cell extracts obtained from 
mammary tissue of white females. The extracts were obtained after the cells had 
been grown in human transformation medium for 12 days in the absence of ALP 
inhibitors, and as described in section 3.2. The cell extracts were divided into 2 
aliquots of 250ul each and to one extract 4ul of PBS was added and to the other 
4ul of a levamisole solution (gives final concentration of 2.0 mM) made up as 
follows: 0.045g of levamisole dissolved in PBS (see section 3.1.5).
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3.7 Localisation of Alkaline Phosphatase Activity
The 3T3-L1 and human preadipocytes were cultured on cover slips in 
small petri dishes under the same conditions described before, and adipogenesis 
was intiated using the previously described methodology (see sections 3.1.4 and 
3.6.4). Cells that had been grown in differentiation medium for at least 7 days 
were used for the subcellular localization of alkaline phosphatase .Tissue culture 
medium was aspirated off cells which were then washed two times with 
phosphate buffered saline solution (PBS), pH 7.4. Cells were then fixed for 15 
minutes at room temperature with a 3% formaldehyde / PBS solution and then 
washed three times with PBS.
Alkaline phosphatase detection was carried out with ELF 97 endogenous 
phosphate detection kit (Molecular Probes). The ELF 97 substrate was diluted 
1:20 in ELF-97 buffer, vortexed and filtered through an ELF 97 spin filter. An 80ul 
aliquot of substrate solution was applied per coverslip and the reaction monitored 
on Carl Zeiss Axiovert 100 M fluorescence microscope. The signal was 
visualized with Hoechst/DAPI filter set with excitation of 365 nm and emission > 
or = 400 nm. After 15 minutes, once sufficient reaction product had formed, the 
cover slips were mounted on microscope slides in ELF 97 mounting medium . 
Omission of substrate produced no labelling .Images were digitally captured 
using Carl Zeiss Axiovision software, version 2.0.5.
Dr Clem Penny performed the image capture of the stained cells with help 
from Mr Aus Ali.
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3.8 The Effect of BMI on ALP and Liver Enzyme Activity In Serum
The finding that ALP was expressed in human preadipocytes led us to 
question whether serum ALP levels may not be associated with body fat mass. 
Total serum ALP level was therefore measured in 101 African subjects of varying 
BMI. Ethical approval for the collection of serum samples was obtained from the 
University of Witwatersrand, Faculty of Health Sciences Human Ethics 
Committee. Informed consent was obtained from each volunteer. .Only subjects 
who had no known liver pathology or bone fractures within the last 2 years were 
included in the study. Bone fracture and liver disease can lead to elevated serum 
ALP levels (Price, 1993) and liver disease can also lead to elevated serum levels 
of albumin, bilirubin, alanine aminoransferae (ALT), total protein and gamma 
glutaryltransferase (GGT). These enzyme levels were therefore also measuerd in 
serum to ensure that none of the volunteers had any liver pathology which may 
lead to elevated ALP levels. Elevated serum liver enzyme concentrations are 
also associated with obesity (Golik et al., 1991), particularly abdominal obesity. 
Therefore, this study also analysed the association of liver enzyme levels with 
BMI and waist-to-hip ratio.
ALP in the serum is mainly derived from the liver, bone and intestine 
(Price, 1993) and the assay used to measure serum ALP cross reacts with all 3 
of these forms of the enzyme. A bone-specific ALP ELISA is available and this 
assay was also used to measure bone ALP. The value derived from the bone 
specific assay was subtracted from that obtained from thre total ALP assay to
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give an estimate of the liver ALP levels in the serum. Intestinal ALP makes up 
less than 15% of the total ALP in serum (Price, 1993).
A small study was undertaken to test the effect of food intake on serum 
total ALP levels. This was performed in order to determine whether non-fasting 
blood samples could be used for the measurement of serum ALP levels in the 
larger study. A total of 12 (10 females) volunteers were used and ALP levels 
were measured in serum after an overnight fast and 60 minutes after breakfast, 
both blood samples being drawn on the same day. The serum total ALP level 
(mean ± SD) was 61.4 ± 17.6 U/l before breakfast and 60.8 ±17.1 U/l after 
breakfast (p=0.43). Thus, food intake had no effect on serum ALP levels and 
therefore in the larger study, non-fasting blood samples were used to determine 
serum levels of total ALP.
Weight and height were measured in 101 African subjects using a 
stadiometer (Modern Scale Co., Johannesburg). Waist-to-hip ratio (WHR) was 
measured standing by taking waist circumference as the midpoint between the 
lower rib margin and the iliac crest and hip circumference as the widest 
circumference of the buttock. A 5ml blood sample was taken from the antecubital 
vein of the forearm from each subject. The sample was immediately centrifuged 
and the serum removed and aliquotted into 2 tubes, one for liver function tests 
and the second for bone-specific ALP measurement. Serum samples were stored 
at -20°C until assayed. Ethical approval for blood sampling was obtained from 
the University of Witwatersrand, Faculty of Health Sciences Human Ethics 
Committee. Informed consent was obtained from each volunteer.
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All following assays were measured in the Chemical Pathology routine laboratory 
using a commercial kit (Roche) on an autoanalyser (Modular, from Roche).
3.8.1. Alanine aminotransferase(ALT) measurement
ALT enzyme catalyzes the following reaction; 
a-ketoglutarate +L-alanine—►L-glutamate+pyruvate
The increase in pyruvate is determined in an indicator reaction catalyzyed by 
lactate dehydrogenase(LDH) as follows;
Pyruvate+NADH+H+ <->L-lactate+NAD+
NADH is than oxidized to NAD. The rate of the photometrically determined NADH 
decrease is directly proportional to the rate of formation of pyruvate and thus the 
ALT activity.
3.8.2. Albumin (ALB) measurement
At the pH value of 4.1 albumin displays a sufficiently cationic character to be able 
to bind with bromcresol green (BCG), an anionic dyestuff, to form a blue -green 
complex.
Albumin+BCG —> albumin BCG complex
The colour intensity of the blue-green colour is directly propotional to the albumin 
concentration and can be determined photometrically
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3.8.3. Gamma-glutamyl-transferase (GGT) measurement
This reaction depends on the ability of gamma-glutamyltransferase to transfer the 
y-glutamyl group of L- y-glutamyl-3-carboxy-4-nitroanilide to glycylgycine. The 
amount of 5-amino-2-nitrobenzoate liberated is propotional to the GGT activity 
and can be determined photometrically. The reaction below describe the whole 
process;
L- y-glutamyl-3-carboxy-4-nitroanilide+ glycylgycine—>■ L- y-glutamyl- 
glycylglycine+5-amino-2-nitrobenzoate.
3.8.4. Total bilirubin (TBil) measurement
Indirect bilirubin is liberated by the addition of a detergent, and the total bilirubin 
is then coupled with 2,5-dichlorophenyl diazonium tetrafluoroborate under 
strongly acidic conditions (pH 1-2) to form the corresponding azobilirubin, as 
described below:
Bilirubin+diazonium ion—>■ azobilirubin
The photometrically determined colour intensity of the red azo-dye is directly 
proportional to the total bilirubin concentration.
3.8.5. Total protein (TP)
Divalent copper reacts in alkaline solution with protein peptide bonds to form the 
characterstatic purple-colored biuret complex. Sodium potassium tartrate 
prevents the precipitation of copper hydroxide and potassium iodide prevents 
autoreduction of copper.
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Protein + Cu+2 —>Cu-protein complex
The colour intensity is directly proportional to the protein concentration which can 
be determined photometrically.
3.9. Statistical Analysis and Data Presentation
The statistical analysis for all experiments was performed using the 
Statistica package (StatSoft Inc., Tulsa, Oklahoma, USA). Differences within 
treatment groups were compared using a paired Students t-test. The effects of 
removing or changing concentrations of the constituents (ie insulin, IBMX and 
dexamethasone) of the transformation medium were analysed using ANOVA.
The inhibtor studies on 3T3-L1 cells were performed a minimum of three times 
for each inhibitor. In human preadipocytes levamisole treatment was performed 
on mammary cells from 9 black and 8 white females. All other inhibitors were 
tested on a minimum of four subjects of each ethnic group. Preadipocytes from 
some patients were sufficient to perform studies with more than one inhibitor. 
Comparisons of means within subject groups were performed by Students paired 
t-test whilst differences between ethnic groups and between preadipocyte- 
isolation sites were compared using Students non-paired t-test..
Relationships between anthropometric variables and liver function were analysed 
by Pearson correlation and multiple regression analysis. Data that was not 
normally distributed was either log transormed or converted to reciprocals, or 
square roots according to the degree of skewness. Differences between groups 
(males versus females, lean versus overweight versus obese) were compared
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using ANCOVA and post hoc comparisons were performed using the Tukey 
honest significant difference (HSD) test for equal N numbers. Data is presented 
for ALP inhibitor studies as histograms and is also presented in numerical form in 
Appendix 2, in an unadjusted form. This data was also expressed as a percent of 
the data obtained on day 0 (set at 100%). The percentage values have only 
been given for the 3T3-L1 levamisole data (see section 4.1.2) as this was only 
experiment in which significant trends were uncovered by expressing data as 
percentages. In all other experiments there were no significant differences in 
observed trends for data expressed unadjusted or as percentages.
93
CHAPTER FOUR
RESULTS
94
Introduction
The initial aim of this research project was to determine whether ALP is 
expressed in 3T3-L1 cells and human preadipocytes, and if so what role does it 
play, if any in intracellular lipid accumulation. An additional aim was to assess 
whether ethnic differences existed in adipogenesis rate in white and black South 
African females. When it became clear that ALP was expressed in human 
preadipocytes, additional aims were added to the project. These were to 
determine whether ALP was expressed in different adipose tissue depots 
(mammary and subcutaneous abdominal) in humans and was the level of activity 
different in the two ethnic groups under investigation. Additionally, since ALP is 
found in human serum and it has been assumed that the principal tissue sources 
for serum ALP were liver, bone and intestine we decided to investigate whether 
adipose tissue also contributed to the ALP present in the circulation.
The data in the Results section has been set out in the following order:
1. Results from 3T3-L1 cells: measurement of presence of ALP activity before 
and during adipogenesis: the effects of ALP inhibitors on lipid accumulation; 
effect of varying concentrations of transformation medium components i.e. 
insulin, IBMX and dexamethasone on lipid accumulation and ALP activity; 
intracellular localisation of ALP.
2. Results from human preadipocytes: ALP activity in mammary tissue 
preadipocytes from black and white females and effects of ALP inhibitors on
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cytoplasmic lipid deposition; intracellular localisation of ALP; ethnic differences in 
ALP activity and rate of intracellular lipid accumulation; detection of ALP activity 
in subcutaneous abdominal adipose tissue preadipocytes isolated from black 
females and effect of ALP inhibitors; comparison of ALP activity and rate of 
intracellular lipid accumulation in the 2 fat depots.
3. Measurement of ALP activity in human serum: differences in ALP and other 
liver enzyme serum levels in lean, overweight and obese subjects; gender 
differences in liver enzyme levels in serum; correlation between BMI and total, 
bone-specific and total-bone specific ALP activity in human serum; correlation 
between level of liver enzymes present in human serum and selected 
anthropometric variables.
The results for all the preadipocyte experiments are shown in this chapter as 
histograms and are also shown in Appendix 2 as means ± SEMs.
4.1. 3T3-L1 study results
As discussed in section 3.1.5, the concentration of ALP inhibitors used in the 
following experiments was determined by reviewing the available literature and 
confirming by performing ALP assays or assessing adipogenesis over a range of 
different inhibitor concentrations. With levamisole, ALP activity was assessed and 
results were as follows: without levamisole, 91.7±11.1 mU/mg cell protein (mean 
±SD) ; 0.5 mM levamisole, 76.7±23.5 ; 1 mM levamisole, 64.1±16.8 ; 2.0 mM 
levamisole , 49.0±9.0. For histidine, 25 mM caused minimal inhibition of 
adipogenesis in 3T3-L1, whilst 50 mM and 100 mM both caused an approximate
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80% inhibition of adipogenesis. Phe Gly Gly at 10, 20, 40, and 80 mM cause no 
inhibition of adipogenesis in 3T3 L1 cells.
4.1.1. Alkaline phosphatase activity is present in 3T3-L1 cells and increases 
during the differentiation process
Alkaline phosphatase activity was detectable in non-differentiated 3T3-L1 cells at 
a level of 1.11 ± 0.62 mU/mg protein (mean ± s.e.m. of 4 experiments). After 3, 7, 
11 and 17 days treatment with differentiation medium the levels of alkaline 
phosphatase activity were: 10.94 ± 2.89 (n=3), 17.16 ± 6.03 (n=4), 22.97 ± 9.19 
(n=4) and 31.2 ± 0.73 mU/mg protein (n=2) respectively and the level of alkaline 
phosphatase activity was significantly different from the level in non-differentiated 
cells from day 3 onwards (p<0.05 for all).Adipogenesis assessed using oil red O 
,also increased over the 17 day period, and was significantly different from the 
level on day zero from day 7 onwards (p<0.01 for all).Figure 4.1 shows the 
parallel relationship between ALP activity and adipogenesis in 3T3-L1.
4.1.2. Effect of ievamisole treatment
In the presence of Ievamisole, ALP activity in the 3T3-L1 cells tended to be lower 
on days 7 and 11 compared to levels in cells not treated with the inhibitor, but 
mean values were not significantly different. Likewise, ALP activity was higher on 
days 3, 7 and 11 compared to activity on day 0, but these differences were not 
statistically different. This lack of significance is a result of the high standard 
errors. Therefore, data was aiso expressed as a percentage of the ALP activity 
obtained on day 0, which was set at 100%. This lowered the standard errors, and
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significant differences were then obtained for ALP activity in absence and 
presence of levamisole on days 7 (898±96% vs. 615±102%, respectively; 
P=0.002) and days 11 (1150±136% vs. 531 ±31%; P=0.01).
Triglyceride content of 3T3-L1 cells in the absence of levamisole was significantly 
higher on days 7 and 11 (both P<0.05) compared to day zero. This was not the 
case on day 3. Statistically significant differences between treatments were 
observed on day 7 and day 11 (both P<0.05), but not on day 3. Levamisole is 
therefore inhibiting both ALP activity and adipogenesis (see figure 4.2A,B).
4.1.3. Effect of Phe Gly Gly treatment
Differentiation in the presence of Phe-Gly-Gly did not lead to any significant 
changes in either alkaline phosphatase activity or level of adipogenesis (see 
figure 4.3A,B). Significant differences were found for ALP activity when treated 
(P<0.05 and P<0.005) and non-treated (both P<0.05) cells on day 7 and day 11, 
respectively, were compared with day zero. Significant differences were also 
found for lipid accumulation when non-treated cells on day 7 (P<0.05) and day 11 
(P<0.005), were compared with day zero. Only treated cells on day 11 (P<0.005) 
showed significantly higher lipid accumulation than cells on day 0.
4.1.4. Effect of histidine treatment
Histidine also inhibited both alkaline phosphatase activity and adipogenesis but 
to a greater extent than did levamisole. Thus, on days 3 , 7, and 11 histidine 
treatment completely blocked the rise in ALP activity, whilst in the absence of
98
histidine, ALP activity was significantly higher than on day zero, after 3 (P,0.05), 
7 (p<0.005) and 11 (p<0.05) days of transformation. Significant differences 
between treatments were observed on days 3 (P<0.05), 7 (p<0.005), and 11 
(p<0.05). Data for the effects of histidine on adipogenesis mirrored those for ALP 
activity.
Light microscopic analysis of lipid droplet formation in the 3T3-L1 cells in the 
presence and absence of histidine and using oil red O to stain for triglyceride, 
demonstrated the strong inhibitory effect of histidine on intracellular triglyceride 
accumulation (See Picture 4.1A,B).
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—  0.6
— 0.4
—  0.2
Figure 4.1 The relation between ALP activity and intracellular lipid accumulation 
in 3T3-L1 cells (red line represents ALP and blue line represents fat 
accumulation). See text in section 4.1.1 for details of number of times experiment 
performed and mean ± SEM values.
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A. Without histidine
B. With histidine
Picture 4.1 A, B shows the effect of histidine treatment on lipid accumulation in
3T3-L1 cells.
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A The Effect of Levarrisole on ALP activity
c
□With Levarrisole DWthoutLsvamsole
B. The Effect of Levamisole on Triglyceride Accumulation
Q
Figure 4.2. Effect of levamisole on: A. ALP activity and B. Lipid accumulation in 
3T3-L1 cells. Each bar represents the mean ± SEM of 4 experiments.
aP<0.05 Vs treated cells bP<0.05 Vs cells on day 0.
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A. The Effect of Phe.Gly.Gly on ALP activity
□  With Phe.Gly.Gly □  Without Phe.Gly.Gly
B. The Effect of Phe.Gly.Gly on Lipid
Accumulation
Figure 4.3. Effect of Phe.Gly.Gly on: A. ALP activity and B. Lipid accumulation in 
3T3-L1 cells. Each bar represents the mean ± SEM of 4 experiments. 
bP<0.05, bbP<0.005 Vs cells on day 0.
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A. The Effect of Histidine on ALP activity
□ With Histidine □  Without Histidine
B. The Effect of Histidine on Lipid Accumulation
Figure 4.4. Effect of Histidine on: A. ALP activity and B. Lipid accumulation in 
3T3-L1 cells. Each bar represents the mean ± SEM of 4 experiments. 
aP<0.05, aaP<0.005, aaaP<0.0005 Vs treated cells; bP<0.05, bbP<0.005 Vs cells on day 0..
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4.1.6. The effect of removing IBMX, dexamethasone, or insulin from the 
transformation medium
These experiments compared four treatments as follows; 0 IBMX (when the 
transformation media had no IBMX), 0 DEXA (when the transformation media 
had no dexamethasone), 0 Insulin (when the transformation media had no 
insulin), and normal transformation media (which contains the normal levels of 
IBMX, DEXA, and insulin). Differences in ALP activity were significant on day 
3(p<0.05) and day 6(P<0.05) compared with day zero, when insulin and 
dexamethasone were removed from the transformation medium, and this was 
also the case for the normal medium. ALP activity on day 6 was higher compared 
to that on day 3 for both the normal medium and the medium lacking 
dexamethasone. This was not the case for the medium lacking insulin. Therefore, 
the removal of dexamethasone has no effect on ALP activity whereas, the 
removal of insulin does have an effect after 6 days. The removal of IBMX from 
the transformation medium resulted in ALP levels on day 3, and day 6 that were 
not different from that on day zero.
Removal of dexamethasone or insulin from transformation medium had no effect 
on adipogenesis. Thus, after 6 days of treatment triglyceride accumulation was 
significantly higher compared to day zero for the normal medium and the 
mediums lacking insulin or dexamethasone. Removal of IBMX from 
transformation medium however, blocked adipogenesis. These results mirrored 
those obtained for ALP activity (see figure 4.5A, B).
105
Lipid
Accum­
ulation
(OD
units)
ALP
(mll/mg
protein)
A. The effect of removing IBMX or insulin or dexamethasone on
lipid accumulation
□  Day 0 □  Day 3 □  Day 6
B. The effect of removing IBMX, or insulin, or dexamethasone on
ALP activity
M edium
Figure 4.5. The effect of removing insulin, IBMX or dexamethasone on: A. Lipid 
accumulation and B. ALP activity in 3T3-L1 cells. Each bar represents the mean 
± SEM of 3 experiments. aP<0.05 Vs day zero, bP<0.05 Vs day 3
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This experiment was performed in order to determine the dose response 
relationship between IBMX and adipogenesis, and whether this relationship was 
similar to the dose response effect on ALP activity. The IBMX concentration 
chosen were 0.17mM, 0.50mM (concentration in normal medium),and 1.5 mM. 
The dexamethasone concentration were also varied and the concentrations 
chosen were 0.023uM, 0.07uM, 0.22uM (concentration in normal medium) and 
0.66 uM.
ALP activity was significantly higher on day 3 (P<0.05) and on day 6 (P<0.05) 
respectively, for medium containing 0.5mM, and 1.5 mM IBMX when compared 
to medium containing 0.17 mM IBMX. Altering dexamethasone concentrations 
had no effect on ALP activity. Adipogenesis also increased with increasing IBMX 
concentrations, but this trend was not as obvious as that seen for ALP activity . 
Changing dexamethasone concentrations had no effect on adipogenesis (see 
figure 4.6A, B).
4.1.7. The dose response effect of IBMX and dexamethasone on
adipogenesis and ALP activity
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A. The effect of level of concentrations of IBMX and
dexamethasone on lipid accumulation
Lipid
"accumula­
tion (OD 
units)
□  Day 0 □  Day 3 □  Day 6
B. The effect of level of concentrations of IBMX and 
dexamethasone on ALP activity
ALP
(mU/mg
protein)
0.22uM DEXA 0.22uM DEXA 0.22uM DEXA 0.66uM DEXA 0.07uM DEXA 0.023uM DEXA
0.17mM IBMX 0.5mM IBMX 1.5mM |BMX 0.5mM IBMX 0.5mM IBMX 1.5mM IBMX
Figure 4.6. The effect of varying concentration of IBMX or dexamethasone on: A. 
Lipid accumulation and B. ALP activity in 3T3-L1 cells. Each bar represents the 
mean ± SEM of 3 experiments.
aP<0.05. aaP<0.005 Vs day 3, 0.17mM IBMX; bP<0.05,bbP<0.005 Vs day 6, 0.17mM IBMX.
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Using the ELF-97 system for localising ALP activity in intact cells, the fluorescent 
end product resulting from ALP, cleavage of ELF-97 resulted in fluorescent 
staining present only on intracellular lipid droplet of 3T3-L1 cells(see picture no 
4.2A.B)
4.1.8. Localisation of ALP activity in 3T3-L1 cells
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Picture 4.2A, B. Fluorescent staining of: A. Alkaline phosphatase activity in 3T3- 
L1 cells, and B. Normal light microscopy image of 3T3-L1 cells. Images in A and 
B are the same.
N=nucleus ; arrow indicates lipid droplets.
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4.2. Human study results
4.2.1. Breast fat tissue experiments
Anthropometric data for 3 of the 28 human subjects from whom mammary tissue 
was obtained, were not available (see Appendix 1, table 1). When data from 
these subjects was removed from the statistical analyses, none of the trends 
observed were changed.
4.2.1.1. Effect of Levamisole
Alkaline phosphatase activity was detected in non differentiated human 
preadipocytes collected from the breast during breast reduction operations.
Its activity increased during the 12 day differentiation process.
In White patients the activity of the enzyme was significantly higher on day 12 for 
the preadipocytes treated with levamisole (P<0.0005) compared with non-treated 
preadipocytes (see figure 4.7A, B). The ALP activity was significantly higher for 
both treated and non treated preadipocytes (P<0.0005), when it was compared 
with undifferentiated preadipocytes on day zero (number of patients was 9) . 
These results conflict with our earlier results for 3T3-L1 cells, where the 
treatment with levamisole inhibited the activity of ALP. In contrast, treatment of 
human preadipocytes with levamisole caused inhibition of adipogenesis in these 
same patients. There were significant differences between the preadipocytes 
treated with levamisole, and non-treated preadipocytes (P<0.0005). The 
adipogenesis results for both treated and non-treated cells were significantly
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higher (P<0.0005), on day 12 when compared with undifferentiated 
preadipocytes on day zero (see figure 4.7A, B).
Similar results were found with preadipocytes collected from Black women. 
Differences in ALP activity were found on day 12 when treated (P<0.05) and non- 
treated cells (P<0.05) were compared with ALP activity on day zero. Significant 
differences were found between treated (P<0.05) and non treated cells on day 
12, with ALP activity again being higher in preadipocytes treated with levamisole 
(Number of patients was 8).
Adipogenesis on day 12 was significantly higher in treated (P<0.005) and non- 
treated cells (p<0.0005) when compared with adipogenesis on day zero. 
Significant differences (see picture number 4.3A.B) were also found on day 12 
between non-treated cells (P<0.0005) and treated cells (see figure 4.8A.B). 
Despite levamisole activating ALP activity it was still able to inhibit adipogenesis, 
as observed in 3T3-L1 cells.
The effect of levamisole treatment on ALP activity in preadipocyte cell extracts 
was also investigated. Five (5) separate extracts were obtained from mammary 
tissue preadipocytes cultured for 12 days in absence of ALP inhibitors in human 
transformation medium. ALP activity was measured in presence and absence of 
2.0mM levamisole. The results (means ± SEMs) were as follows:
Treatment ALP activity (U/L extract)
Without levamisole 94.8 ± 30.4
With levamisole 48.8 ± 17.5*
*P=0.025 vs. without levamisole
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Levamisole caused a significant (50.4 ± 5.2%) inhibition of ALP activity in the cell 
extracts.
4.2.1.2. Effect of Phe.Gly .Gly
Treating the preadipocytes collected from White and Black females with the 
tissue specific ALP inhibitor Phe Gly Gly did not effect either adipogenesis (see 
picture number 4.4A.B) or alkaline phosphate activity (number of patients in 
these experiments were 4 for each race). The results were significantly higher in 
cells collected from White (P<0.05), and Black subjects (P<0.05), when 
compared with day zero for both adipogenesis and ALP activity respectively(see 
figures 4.9A,4.9B,4.10A,4.1 OB) .
4.2.1.3. Effect of Histidine;
Treating preadipocytes with histidine demonstrated inhibition in the activity of 
alkaline phosphatase when comparing non-treated and treated cells in white 
(P<0.05),and black subjects (P<0.0005) on day 12. ALP activity on day 12 in 
treated cells collected from black subjects was less than that on day zero 
(P<0.005; see figure number 11B.12B).
Histidine treatment, also caused inhibition of adipogenesis (see figures 11A.12A 
and picture number 4.5A,B), for both white (P<0.05),and black 
subjects(P<0.0005). These results were not surprising, as the same effect has 
been shown with our earlier results using the same inhibitor with 3T3-L1.The 
number of women in histidine experiment were 4 black women and 4 white 
women.
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A. W ithout levamisole (control).
B. With levamisole.
Picture 4.3A,B The effect of: A. Absence and B. Presence of levamisole on lipid
accumulation in human preadipocytes.
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A. W ithout Phe Gly Gly (control).
B. With Phe Gly Gly.
Pictures 4.4A,B. The effect of: A. Absence and B. Presence of Phe.Gly.Gly on
lipid accumulation in human preadipocytes.
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A. W ithout histidine (control).
r
B. With histidine.
/
S j
Pictures 4.5A, B. The effect of: A. Absence and B. Presence of histidine on lipid
accumulation in human preadipocytes.
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Alkaline phosphatase localized on lipid droplets
Immunocytochemical analysis of differentiated human preadipocytes showed that 
ALP was present on the lipid droplets as shown in picture number 4.6A,B-
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A. Fluorescent micrograph of human preadipocytes stained for ALP
B. Normal light micrograph of human preadipocytes
Picture 4.6A,B. Fluorescent staining (A) of alkaline phosphatase activity in 
human preadipocytes. Normal light microscopy image of human preadipocytes 
(B). Images in A and B are the same .
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A. Effect of levamisole treatment on lipid accumulation in 
preadipocytes from mammary tissue obtained from white
females
□  With Levam isole □  Without Levam isole
B. The effect of levamisole on ALP activity in 
preadipocytes from mammary tissue taken from white
women
Figure 4.7 A, B. The effect of levamisole on: A. Lipid accumulation and B. ALP
activity in preadipocytes isolated from the mammary tissue of 8 white females.
Each bar is m ean ±  SEM . aP<0.05 , aaP < 0.005  Vs day zero and bP < 0.05 , bbP < 0.005  Vs treated
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A .The Effect Of Levamisole On Triglyceride Accumulation
In Mammary Tissue Taken From Black Women
c/>
□ With Levamisole □ Without Levamisole
B. The Effect Of Levamisole On ALP Activity In 
Mammary Tissue Taken From Black Women
Figure 4.8 A, B. The effect of levamisole on: A. Lipid accumulation and B. ALP
activity in preadipocytes isolated from the mammary tissue of 9 black females.
Each bar is m ean ± SEM . aP<0.05 , aaP < 0.005  Vs day zero; and bP<0.05 , bbP <0.005, Vs treated.
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A. The effect of Phe.Gly.Gly. on lipid accumulation In 
mammary tissue taken from white women
□  With Phe.Gly.Gly □  Without Phe.Gly.Gly
The effect of Phe.Gly.Gly. on ALP activity in mammary 
tissue taken from white women
Figure 4.9 A, B. The effect of Phe.Gly.Gly on: A. Lipid accumulation and B. ALP
activity in preadipocytes isolated from the mammary tissue of 4 white females.
aP < 0.05  Vs day zero. Each bar is a m ean ± SEM .
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A. The Effect of Phe.Gly.Gly on Triglyceride 
Accumulation in Mammary Tissue taken from Black
Women
□  With Phe.Gly.Gly □  W ithout Phe.Gly.Gly
B. The Effect of Phe.Gly.Gly on ALP Activity in Mammary 
Tissue taken from Black Women
Figure 4.10 A, B. The effect of Phe.Gly.Gly on: A. Lipid accumulation and B. 
ALP activity in preadipocytes isolated from the mammary tissue of 4 black 
females.
aP<0.05, aaP<0.005 Vs day zero. Each bar is a mean ± SEM.
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A. The Effect o f Histidine on Trigiyceride Accumulation
in Mammary Tissue taken from White Women
</>
□ With Histidine □ With Out Histidine
B. The Effect of Histidine on ALP Activity in Mammary Tissue
taken from White Women
ALP
(mU/mg
protein)
Figure 4.11 A, B. The effect of Histidine on: A. Lipid accumulation and B. ALP
activity in preadipocytes isolated from the mammary tissue of 4 white females.
aP < 0 .0 5  Vs day zero; and bP < 0.05  Vs treated. Each bar is a m ean ± SE M  .
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A. The Effect of Histidine on Triglyceride Accumulation
of Mammary Tissue taken from Black Women
B. The Effect of Histidine on ALP Activity in Mammary 
Tissue from Black Women
Figure 4.11 A, B. The effect of Histidine on: A. Lipid accumulation and B. ALP
activity in preadipocytes isolated from the mammary tissue of 4 black females.
aP<0.05 , aaP <0.005, Vs day zero; and bP<0.05 , bbP <0.005  Vs treated. Each bar is a m ean ± SEM .
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4.3. Ethnic differences in ALP activity and adipogenesis
Interesting significant differences were observed for ALP activity and 
adipogenesis between preadipocytes collected from black and white women. 
These differences are described bellow.
4.3.1. Ethnic differences during levamisole treatment
Significant differences between black and white subjects were seen on day zero 
for both ALP activity (P<0.0005), and adipogenesis (P<0.005) as shown in figure 
16A.16B. Differences in ALP activity on day 12 were observed when black non- 
treated preadipocytes (P<0.05), were compared with white non-treated 
preadipocytes. Adipogenesis on day zero was significantly higher in black 
preadipocytes (P<0.005) compared with white preadipocytes, while on day 12 a 
significant difference was observed when non-treated preadipocytes from black 
subjects (P<0.0005) were compared with white subjects(see figure 13A,B).
4.3.2. Ethnic differences during Phe Gly Gly treatment
As has been seen before tissue specific ALP inhibitor Phe Gly Gly, did not show 
any effect on either ALP activity or adipogenesis. However, significant ethnic 
difference has been shown between white and black subjects. Differences were 
highly significant in black compared with white subjects on day zero for both ALP 
activity (P<0.0005) and adipogenesis (P<0.0005). Again differences were highly 
significant on day 12 for treated and non treated preadipocytes collected from
125
black .when compared with white subjects for both ALP activity (P<0.005) and 
adipogenesis (P<0.005 see figure 14 A.B).
4.3.3. Ethnic differences during histidine treatment
Differences in ALP activity were highly significant when preadipocytes from black 
females were compared with those from white subjects (P<0.0005) on day zero. 
On day 12 differences were only significant when non-treated preadipocytes from 
black females were compared with non-treated preadipocytes from white 
subjects (P<0.005).
During adipogenesis experiments, significant differences were seen on day zero 
(P<0.05). On day 12 significant differences were observed when non-treated 
cells collected from black subjects were compared with their counterparts 
collected from white subjects (P<.0005; see figure 15A,and 15B).
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A. Ethnic Differences in Lipid Accumulation During 
Levamisole Treatment
□ With Levamisole White □ With Out Levamisole White
□ With Levamisole Black □With Out Levamisole Black
B. Ethnic Differences In ALP Activity During Levamisole
Treatment
Figure 4.13 A, B. Levamisole effects on: A. Lipid accumulation, B. ALP activity in 
preadipocytes taken from mammary tissue of 9 black and 8 white females. 
aP<0.05, aaP<0.005, Vs white females, day 0 and bP<0.05, bbP<0.005 Vs white females day 12. 
Each bar is a mean ± SEM..
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A. Ethnic Differences in Lipid Accumulation During
Phe.Gly. Gly Treatment
□  With Out Ph.Gly.Gly W hite D W ith  Ph.Gly.Gly White
□  With Out Ph.Gly.Gly Black □  With Ph.Gly.Gly Black
B. Ethnic Differences in ALP Activity During Phe.Gly.Gly
Treatment
Figure 4.14 A, B. Phe Gly.Gly effects on: A. Lipid accumulation, B. ALP activity 
in preadipocytes taken from mammary tissue of 4 black and 4 white females. 
aaP<0.005 Vs white females, day zero and bP<0.05 Vs white females, day 12. Each bar is a 
mean ± SEM.
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A. Ethnic Differences in Triglyceride Accumulation During Histidine
Treatment
Lipid 
accumu­
lation (OD 
units)
B. Ethnic Differences in ALP Activity During Histidine
Treatment
Day 0 Day 12
□ With Histidine White □ With Out Histidine White
□ With Histidine Black □ With Out Histidine Black
Figure 4.15 A, B. Histidine effects on: A. Lipid accumulation, B. ALP activity in 
preadipocytes taken from mammary tissue of 4 black and 4 white females. 
aP<0.05, aaP<0.005, Vs white females, day zero and bP<0.05, bbP<0.005 Vs white females day 
12. Each bar is a mean ± SEM.
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.4.4. Abdominal subcutaneous fat tissue results;
The effect of levamisole on alkaline phosphatase activity was studied using
preadipocytes isolated from 4 obese black women. Preadipocytes treated with 
levamisole had higher ALP activity compared with non treated preadipocytes 
when ALP activity was measured on day 12 (P<0.005).These results contrast 
with the inhibition of adipogenesis observed in treated preadipocytes when 
compared with non treated preadipocytes (P<0.05). Significantly higher ALP 
activity was observed for both treated and non-treated cells on day 12 when 
compared with ALP activity on day zero(P<0.05 for both). These results parallel 
our earlier results collected from breast tissue for both white and black subjects .
Histidine treatment of human abdominal preadipocytes showed inhibition of both 
adipogenesis(non-treated Vs treated cells P<0.0005) and ALP activity(non- 
treated cells P<0.0005) .These results parallel the earlier results collected from 
breast tissue for both white and black subjects(see figures 4.16A.4.16B and 
4.17A.4.17B).
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A. The Effect of Levamisole on Lipid Accumulation in
Abdominal Tissue taken from Black Women
□ With Levamisole □ Without Levamisole
B. The Effect of Levamisole on ALP activity in 
Abdominal Tissue taken from Black Women
Figure 4.16 A, B. The effect of levamisole on: A. Lipid accumulation and B. ALP 
activity in preadipocytes isolated from abdominal tissue of 4 black females. 
aP<0.05 Vs cells on day zero and bP<0.05 Vs treated cells. Each bar is a mean ± SEM.
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A. The Effect of Histidine on Lipid Accumulation In
Abdominal Preadipocytes taken from Black Women
B. The Effect of Histidine on ALP Activity In 
Abdominal Preadipocytes taken from Black Women
Figure 4.17 A, B. The effect of levamisole on: A. Lipid accumulation and B. ALP 
activity in preadipocytes isolated from abdominal tissue of 10 black females. 
aP<0.05, aaaP<0.005 Vs day zero; and bbP<0.005, bbbP<0.0005 Vs treated cells. Each bar is a 
mean ± SEM.
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Differences in adipogenesis between black abdominal subcutaneous 
preadipocytes and black mammary gland preadipocytes were not significant
during histidine treatment, but significant differences were observed on day zero 
between the depots with levamisole treatment. No differences were seen with 
any of the treatments for ALP activity (see figures 4.18A, 4.18B and, 4.19A, 
4.19B). When data was combined from all inhibitor studies and comparison made 
on day zero and day 12 for treatments without inhibitors , significant differences 
were only observed for adipogenesis on day zero : mammary preadipocytes,
0.30 ± 0.006 OD units; abdominal preadipocytes, 0.24±0.02 OD units (p=0.003).
4.5. The effect of the site on adipogenesis and ALP activity
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A. The Effect of Site of Recovery of Preadipocytes on Lipid Accumulation In 
Black Women during Levamisole Treatment
B.The Effect of Site of Recovery of Preadipocytes on ALP 
Activity in Black Women during Levamisole Treatment
□ With Levamisole, Mammary □ Without Levamisole, Mammary
□ With Levamisole, Abdominal □ Without Levamisole, Abdominal
Figure 4.18A, B. The effect of site of recovery of preadipocytes treated with 
levamisole on: A. Lipid accumulation and B. ALP activity in black females (N=9 
for mammary and N=4 for abdominal).
aaP<0.005, Vs abdominal on day zero. Each bar represents mean ± SEM.
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A.The Effect of Site of Recovery of Preadipocytes on Lipid 
Accumulation in Black Women during Histidine Treatment
□ With Histidine, Mammary □ Without histidine, Mammary
□ With Histidine, Abdominal G Without Histidine, Abdominal
B. The Effect of Site of Recovery of Preadipocytes on 
ALP Activity in Black Women During Histidine Treatment
Figure 4.18A, B. The effect of site of recovery of preadipocytes treated with 
histidine on: A. Lipid accumulation and B. ALP activity in black females (N=4 for 
mammary and N=10 for abdominal).
aaP<0.005, Vs abdominal on day zero. Each bar represents mean ± SEM.
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Table 4.1.shows that females were older, shorter, heavier, and had a greater 
waist-circumference, but had lower waist-hip ratio than males. Table 4.2 
demonstrates that females had higher total protein but lower albumin levels than 
male subjects. Data from table 4.3, shows that with increasing BMI, there was an 
increase in age weight, waist and hip circumferences, but height decreased.
This table also shows that total ALP, and total-bone ALP levels were higher in 
obese than lean subjects.
Table 4.4 shows that age correlates positively with all measures of ALP, and with 
total bilirubin and weakly (P=0.087) with albumin levels. BMI, correlates positively 
with total-bone ALP, and there is a weak positive correlation with total ALP 
(P=0.063). There is a strong negative correlation between BMI and total bilirubin 
(P=0.02), and a weaker negative relationship with albumin levels (P=0.051). 
Waist-hip ratio, displayed a strong positive relationship with albumin (P=0.003) 
and ALT (P=0.0001) levels and a weak positive relationship with total bilirubin 
levels (P=0.07). Multivariate regression analysis, using sex, age, BMI, and waist- 
hip ratio, as independent variables, demonstrated that ALP measurements 
correlated positively with age, but not with any of the anthropometric variables. 
The main determinant of albumin levels was found to be sex (P<0.0001), with a 
weaker input from waist-hip ratio (P=0.07). ALT levels were predominantly 
determined by waist hip ratio (P=0.0002) and total bilirubin concentrations 
demonstrated a weak relationship with waist-hip ratio (P=0.06).
4.6. The effect of weight on ALP activity and liver enzymes
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A. Anthropometric data for females
Variab les N N um ber Mean
A ge 75 41.08 ± 10.062°
H eight 75 1.575 ± 0 .0 6 6 8 b
W eight 75 78.874 ± 2 0 .099b
BMI 75 31.79 ±  8 .055b
W aist 75 90.086 ± 15.897°
Hip 75 108.88 ± 15.595
W aist-H ip 75 0.8340 ± 0 .1 4 5 0 °
B. Anthropometric data for males
Variab les N N um ber Mean
Age 26 33.961 ± 9 .6 3 1
Height 26 1.685 ± 0 .6 5 3
W eight 26 64.33 ± 10.799
BMI 26 22.64 ± 3 .6 1 0
W aist 26 79.36 ± 9 .1 1 6
Hip 26 89.22 ±  7 .284
W aist-H ip 26 0.89 ± 0 .934
Table 4.1: Anthropometric measurements for A. Females and B. Males 
ap<0.005 Vs males 
bp<0.0005 Vs males
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A. Liver function tests for females
Variab les N num ber Mean M edian M inim um M axim um
Total ALP 74 72.432 ± 22.807 72 33 142
Bone A LP 74 32.97 ± 1 2 .9 6 30 15 66
Tota l-B one A LP 73 40.48 ± 17.22 39 15 121
TO TPR 74 80.229 ± 9 .380a 79 67 123
A LB U M IN 74 41.229 ± 3 .556b 42 25 49
ALT 74 13.702 ± 5 .7 3 0 12.5 5 42
TO TB ILU R 74 7.121 ± 3 .7 5 9 6 2 20
G GT 74 42.067 ± 4 9 .8 8 8 25 7 286
B. Liver function tests for males
V ariab les N num ber Mean M edian M inim um M axim um
Total ALP 26 69.807 ± 18.639 65 47 114
Bone A LP 26 33.042 ± 10.07 31 20 55
Tota l-B one A LP 26 33.45 ± 9 .9 4 31 21 63
TO TPR 26 75.961 ± 4 .6 1 7 76 66 87
A LB U M IN 26 45.692 ± 2.222 46 41 50
A LT 26 16.192 ± 5 .8 1 0 15 10 39
TO TB ILU R 26 8.423 ±4 .0 41 7 2 21
G G T 26 31.961 ± 2 7 .1 6 2 22.5 11 138
Table 4.2: ALP and liver enzyme data for A. Females and B. Males 
ap<0.005 Vs males 
bp<0.0005 Vs males
Data corrected fro age, BMI, and waist-hip ratio.
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A. Anthropometric data for different BMI groups
V ariab les Lean (n=37) O verw eight (n=22) O bese (n=41)
A ge 35.6 ±  10.3 39.2 ± 9.7 42.7 ± 9 .84aa
H eight 1.63 ± 0 .0 9 1.61 ± 0 .0 6 1.57 ± 0 .0 6 5 aaab
W eig h t 58.3 ± 7 .7 72.7 ± 6 .4 5 ^ 92.03 ±16.71aaa' bbb
BMI 21.9  ± 1.98 27.7 ± 1.39aaa 37.4 ± 6 .6aaabbb
W ais t 74.7 ± 8.48 85.5 ± 7 .35aaa 99.92 ± 12.85aaa bbb
Hip 89.2 ± 7 .2 101.8 ± 6 .6 aaa 118.4 ± 13.24aaa bbb
W ais t-H ip 0.844 ± 0 .1 4 0.8429 ± 0.09 0.85 ± 0.15
B. Liver function data for different BMI groups
V ariab les Lean (n=37) O verw eight (n=22) O bese (n=41)
Total A LP 66.6 ± 2 2 .2 69.0  ± 21.8 76.5 ± 19.5a
B one A LP 31.3 ± 12.2 32.8 ±  10.4 34.6 ± 13.2
T o ta l-B one  A LP 35.3 ± 1 8 .6 36.3 ±  13.9 42.99 ±  13.3a
Total Protein 79.0 ± 9.0 82.1 ±  11.9 77.5 ± 5.3
A lbum in 42.7  ± 4 .9 6 42.6  ± 3.7 41.97  ± 2.5
A LT 14.6 ± 6 .2 14.8 ± 4.6 13.9 ± 6.2
Total B ilirubin 8.3 ± 4 .5 7.7 ± 3.6 6 .6  ± 3.25
G G T 25.8 ± 1 3 .9 7 41.6  ± 41.9 50.6 ± 60.5
Table 4.3: Anthropometric (A) and liver enzyme differences (B) between different 
BMI groups
ap<0.05, aap<0.005, aaap<0.0005 vs lean; bp<0.05 and bbbp<0.0005 vs overweight 
Data corrected for age and sex.
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Table 4.4. Univariate regression analysis of liver function tests .
Log TALP Log BALP Log T-BALP Sqrt Alb Log ALT Log TBilr LogGGT
Log A ge r=0.33
p=0.001
r=0.27
p=0.006
r=0.39
p<0.0001
r=-0.17
p=0.087
NS r=-0.20
p=0.044
NS
RecBM I r=-0.19
p=0.063
NS r=-0.22
p=0.03
r=0.20
p=0.051
NS r=0.23
p=0.02
NS
R ecW H R NS NS NS r=-0.29
p=0.003
r=-0.41
p<0.0001
r=-0.18
p=0.07
NS
Rec = recipracal 
Sqrt = square root 
NS = P>0.10
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Table 4.5. Multivariate regression analysis of liver function tests.
Model
number
Dependent
variable
Independent
variable
B-value
(p-value)
R-value
(p-value)
1 Log TALP Sex
Log Age 
Rec BMI 
Rec WHR
0.03 (0.81) 
0.40 (0.0001) 
-0.08 (0.48) 
-0.11 (0.27)
0.44
(0.0004)
2 Log BALP Sex
Log Age 
Rec BMI 
Rec WHR
0.17 (0.18) 
0.32 (0.002) 
-0.11 (0.35) 
-0.06(0.55)
0.35
(0.013)
3 Log T-BALP Sex
Log Age 
Rec BMI 
Rec WHR
-0.03 (0.79) 
0.36 (0.0006) 
-0.09 (0.45) 
-0.08 (0.40)
0.43
(<0.0001)
4 Log ALT Sex
Log Age 
Rec BMI 
Rec WHR
0.12 (0.34) 
0.002 (0.98) 
0.06 (0.62) 
-0.38 (0.0002)
0.44
(0.0005)
5 Log TBilr Sex
Log Age 
Rec BMI 
Rec WHR
-0.02 (0.85) 
-0.15 (0.14) 
0.19 (0.11) 
-0.19(0.06)
0.33
(0.03)
6 Sqrt Alb Sex
Log Age 
Rec BMI 
Rec WHR
0.55(<0.0001) 
-0.05 (0.60) 
-0.13(0.22) 
-0.16(0.07)
0.57
(<0.0001)
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Introduction
The increasing worldwide prevalence of obesity (Seidell, 2001) and obesity- 
related disorders [type 2 diabetes mellitus, hypertension and ischaemic heart 
disease (Zimmet et al., 2001)] has led to major research interest in the control 
of adipose tissue mass and how increased adiposity leads to insulin 
resistance and the associated metabolic disorders. Weight gain and obesity 
occur when energy intake exceeds energy expenditure, and excess energy is 
deposited in adipocytes. At the cellular level obesity is characterized by both 
adipocyte hypertrophy and increased number of adipocytes (Hirsch and 
Batchelor, 1976; Ginsberg-Fellner and Knittle, 1981). New adipocytes arise in 
the process of differentiation of preadipocytes. Over the past decade there has 
been an explosion of knowledge about the intrinsic regulatory mechanisms 
determining adipocyte differentiation (Darlington et al.,1998; Fajas et al.,1998; 
Ruesch and Klemm, 1999). It has been determined that adipocyte differentiation 
is a highly regulated processes that involves sequential activation of several 
transcription factors, such as C/EBP |3, C/EBP a, and PPAR y and induction of 
highly specific proteins such as GLUT-4 , FAS , and others (Spiegelman and 
Flier, 1996; Fajas et al., 1998; Hauner, 1990). It was believed that only early- 
onset obesity was associated with adipocyte hyperplasia whereas maturity-onset 
obesity was believed to result solely from adipocyte hypertrophy (Hirsch and 
Knittle, 1970; Salans et al., 1973). However, studies have shown that an increase 
in fat cell number appears to be well correlated with severity of human obesity in 
adult life (Hirsch and Batchelor, 1976). Moreover, specific early differentiation
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genes have been reported to be expressed in adipose tissue from very old 
mice (Kirkland et al. 1990). In addition fat cell precursors, such as stromal- 
vascular cells collected from adult human adipose tissue can be fully 
differentiated into mature adipocytes in vitro (Hauneret al., 1989). Furthermore, 
adipocyte development has been shown to depend on preadipocyte recruitment 
in vivo. Although the relative contribution of adipocyte hypertrophy versus 
hyperplasia to human adiposity is unknown, the capacity to generate new 
adipocytes from precursor cells persists throughout life and clearly plays a role 
in regulating adipose tissue mass.
The present study demonstrates that alkaline phosphatase plays a key role in 
the control of preadipocyte intracellular lipid accumulation and therefore this 
enzyme may be a prime site for the future development of therapeutic 
interventions for obesity and comorbid diseases.
5.1. 3T3-L1 studies
The 3T3 -L1 cell line is a useful model of cellular differentiation, in which 
inducers such as dexamethasone in combination with isobutylmethyl xanthine 
(IBMX), and insulin promote a highly differentiated state in which the cells 
accumulate lipid. The capacity to stain the cells for lipid with oil red O provides a 
method for the determination of the major morphological change that occurs 
during adipogenesis, intracellular lipid accumulation.
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5.1.1. The role of alkaline phosphatase in 3T3-L1 intracellular lipid 
accumulation
The first study has shown that an alkaline phosphatase isozyme that is inhibited 
by levamisole and histidine but not by Phe-Gly-Gly is expressed in the 3T3-L1 
cell line. This is characteristic of the murine tissue nonspecific isozyme of alkaline 
phosphatase (Haneji et ai., 1983; Ohkubo et al., 2000), which shares 90% amino 
acid-sequence homology with the human isozyme (Terao and Mintz, 1987). 
Furthermore, the activity of this enzyme is increased during adipogenesis. This is 
the first study to demonstrate this and is also the first to show that inhibition of 
alkaline phosphatase with levamisole or histidine reduces intracellular triglyceride 
deposition. Furthermore, the localisation of alkaline phosphatase to the 
triglyceride-storing lipid droplets is very suggestive of this enzyme playing a direct 
role in the intracellular accumulation of triglyceride. It is of interest to note that 
intestinal alkaline phosphatase has been indirectly linked to lipid transport in gut 
enterocytes (Zhang et al., 1996), and is found on the membrane surrounding lipid 
droplets in these cells.
Alkaline phosphatase has been the subject of intensive research due to its wide 
tissue distribution (McComb, 1979), clinical utility as a marker of liver and bone 
disorders (Wolf, 1986), and its early , controlled expression during defined stages 
of mammalian embryogenesis (McComb, 1979; Hahnel et al., 1990; McDougall 
et al., 1998). However this is the first study to demonstrate a possible role for 
alkaline phosphatase in the adipocyte differentiation pathway.
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The results from all these experiments have shown increasing activity of 
alkaline phosphatase with adipogenesis. Inhibition of alkaline phosphatase 
using levamisole was paralleled with inhibition of adipogenesis. Levamisole has 
been used widely as an inhibitor for tissue nonspecific alkaline phosphatase.
Levamisole is known to have a number of other effects apart from inhibition of 
alkaline phosphatase. In particular, it is an agonist of both adrenergic and 
nicotinic receptors (Hsu, 1980). Also, levamisole has been demonstrated to 
increase the activity of both glycogen synthase in rat adipocytes (Basi et al.,
1994) and pyruvate dehydrogenase in rat fat pads (Thomaskutty et al., 1993). 
Therefore, the inhibitory effect of levamisole on intracellular lipid accumulation in 
the 3T3-L1 cell line may conceivably be related to its non-alkaline phosphatase 
related activities. Another inhibitor of tissue nonspecific alkaline phosphatase that 
does not have these side effects i.e. histidine was therefore used. Results from 
these experiments were very similar to those obtained with levamisole. However, 
histidine also has other effects apart from inhibiting ALP, particularly inhibition of 
the amino acid System A transporter (SAT2) (Rae et al., 2003). SAT2 is known 
to be expressed in 3T3-L1 cells (Hyde et al., 2001) and its activity upregulated 
during adipogenesis (Su et al., 1998). Therefore, the ability of both levamisole 
and histidine to block ALP activity and reduce intracellular lipid accumulation in 
3T3-L1 cells, although suggestive is not conclusive evidence that ALP is a prime 
modulator of this process.
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In the present study, adipogenesis was measured using the triglyceride specific 
dye, oil red O. This method assesses intracellular triglyceride accumulation 
during the adipogenic process. However, as demonstrated by microarray (Burton 
et al., 2004) and proteome analysis (Welsh et al., 2004), adipogenesis in 3T3-L1 
cells involves the up- and down-regulation of many other genes and enzyme 
systems besides those involved in lipid accumulation. Thus, it is possible that 
ALP may only be affecting lipid deposition and none of the other systems 
involved in adipogenesis. This can be tested by measuring the expression of 
other proteins that are known to be up-regulated during adipogenesis, such as 
PPARgamma, fatty acid binding protein-1 (FABP1) and glycerol 3-phosphate 
dehydrogenase (Gregoire et al., 1998).
The mechanism by which alkaline phosphatase may influence 
lipid accumulation in the 3T3-L1 cell line is not known. Its enzymatic activity not 
only includes an ability to hydrolyse organic phosphate at alkaline pH but also 
phosphotransferase, pyrophosphatase and adenosine-5’-triphosphatase 
(ATP’ase) activities (Granstrom, 1982; Pizauro et al., 1992). Thus, the 
stimulation of lipid accumulation by alkaline phosphatase must involve either an 
alteration in the phosphorylation state of surrounding proteins or the 
hydrolysis of ATP. The localisation of alkaline phosphatase to the membrane 
surrounding the lipid droplet suggests that it may modify biomolecules that are 
either anchored to or interact with this membrane. Studies have shown that 
the membrane surrounding the lipid droplets of adipocytes contain perilipin
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(Greenberg et al., 1991), adipocyte differentiation-related protein (ADRP) 
(Brasaemie et al., 1997), caveolin (Brown, 2001) and vimentin (Blanchette- 
Mackie et al., 1995). Perilipin (Greenberg et al., 1991), caveolin (Mastick et 
al., 1995) and vimentin (Brandes et al., 1993) are all known to be 
phosphoproteins.
The murine preadipocyte cell line 3T3-F442A is similar to the 3T3-L1 cell line 
but unlike the latter requires the presence of growth hormone for the induction 
of adipogenesis (Sumantran et al., 1992). Studies have shown that the 3T3- 
F442A cell line can be stimulated to differentiate along the osteoblast pathway 
by treatment with bone morphogenetic protein (BMP)-2 and retinoic acid (Ji et 
al., 2000; Skillington et al., 2002). These factors induce expression of the 
early osteoblast differentiation marker, alkaline phosphatase as well as 
osteocalcin and collagen I (Skillington et al., 2002). Thus, preadipocytes can 
be induced to express alkaline phosphatase during differentiation into 
adipocytes or osteoblasts. Furthermore, inhibition of alkaline phosphatase 
activity in osteoblastic cell lines leads to decreased calcium uptake and 
reduced cellular mineralization (Fukayama and Tashjian, 1990; Iba et al.,
1995). Transfection of alkaline phosphatase cDNA into alkaline phosphatase 
negative cells promotes both calcium and phosphate uptake (Yoon et al., 
1989). Therefore, alkaline phosphatase does play an important role in the
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differentiation pathway involved in osteoblast maturation and may also be 
involved in the accumulation of intracellular triglyceride during preadipocyte 
differentiation.
5.1.2. Changing constituents of 3T3-L1 transformation medium
In this study we tried to find out which factor in the transformation cocktail is 
the most important for the transformation of 3T3-L1 preadipocytes and for 
increasing ALP activity . As shown in the results (4.5A.B and ,4.6A,B) we found 
that removing IBMX from the cocktail did not allow the cells to differentiate, and 
significant decreases in both ALP activity and adipogenesis were observed. 
IBMX inhibits soluble cyclic nucleotide phosphodiesterase activity and 
results in increased intracellular cAMP levels. cAMP increases the 
synthesis of lipogenic enzymes, indicating that the presence of agents 
that increase cAMP levels are apparently important for full differentiation 
(Spiegelman and Green 1981).
At the nuclear level, treatment with IBMX results in activation of the related 
transcriptional factors C/EBP 6 and/EBP p which induce transcription of C/EBP 
a and PPAR y. cAMP may be a major factor involved in the transcriptional 
regulation during early preadipocyte differentiation. An increase in intracellular 
cAMP concentration during early differentiation is required for optimal adipose 
conversion in 3T3-L1 preadipocytes. It's main function may be to activate cAMP 
response element binding protein (CREB) which is activated by cAMP through
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protein kinase A, or calcium/calmodulin -dependent protein kinase to activate the 
expression of many genes (Roesler et al., 1988). Furthermore, treatment of 
confluent 3T3-L1 with low concentrations of cAMP potentiated the effect of insulin 
on differentiation .The duration of exposure to IBMX is also critical. Prolonged 
exposure to IBMX during 3T3-L1 differentiation can result in cell detachment and 
decreasing differentiation.
It has been demonstrated that cAMP causes a stimulation of ALP activity in 
cultured mouse L-cells. Induction of the enzyme was dependent upon de novo 
RNA and protein biosynthesis (Firestone and Heath, 1981). Like many other 
studies Firestone and Heath (1981) have shown that ALP induced in L-cells is a 
glycoprotein and is associated with the plasma membrane. Tissue non-specific 
ALP activity in the murine L929 fibroblast cell line is induced by all trans-retinoic
c c
acid at concentrations between 10 and 10 M. At lower concentrations, 
retinoic acid is capable of inducing this enzymic activity on its own but also 
increases cyclic AMP mediated induction of ALP. This effect can be observed 
after incubation of retinoic acid with dibutyryl cAMP, 8-bromo cAMP or forskolin. 
This synergism is dependent on the order of addition of retinoic acid and the 
activator of the cAMP pathway. Addition of the two reagents together, or addition 
of cAMP before retinoic acid (but not addition of retinoic acid before cAMP) is 
necessary to produce this synergistic interaction (Gianni et al., 1993). It is 
therefore possible that one of the other mechanisms by which IBMX stimulates 
adipogenesis is via increasing cAMP levels which in turn induces ALP 
expression.
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Removing dexamethasone from the transformation medium appeared to have a 
minimal effect on adipogenesis or ALP activity. Dexamethasone may effect 
differentiation negatively via affecting cAMP metabolism as well as other 
processes in the differentiated cells (Elks and Manganiello, 1985).
Removal of insulin from the media produced a minimal effect on adipogenesis 
and ALP activity . One study has shown that insulin is not required for 
adipogenesis in the 3T3-L1 cell line (Fong, 1990). However, insulin or insulin like 
growth factor-1 promote adipocyte differentiation in humans by activating 
phosphotidyl inositol 3-kinase ( PI3-kinase) and increasing Akt activity.
Modulation of the activity of the fork head transcriptional factor Fox 1, appears to 
be necessary for insulin to promote adipocyte differentiation.
The present study has shown that IBMX is an important regulator of both 
intracellular lipid accumulation and ALP activity in 3T3-L1 cells and that 
manipulation of the former also effects ALP activity. However, it should be noted 
that altered levels of lipid accumulation have only been studied using the 
manipulation of one factor i.e. IBMX and therefore it is not known whether 
manipulating other factors that effect adipogenesis, such as the 
thiazolidinediones, will have similar effects to IBMX.
151
5.2. Human studies
5.2.1. Human preadipocyte experiments
There are two important factors in the study of differentiation, the simplicity of the 
system, and the flexibility of the cells to differentiate under simple culture 
conditions. The majority of stromal cells present in human adipose tissue are 
able to undergo adipose differentiation, under serum-free chemically defined 
culture conditions. This cellular fraction appears to be by far more 
homogeneously composed of specific adipose precursor cells than originally 
believed. To ensure that ALP is presents in human preadipocytes and has the 
same relation with adipogenesis as in the 3T3-L1 cells, we repeated the same 
treatments with human preadipocytes.
5.2.1.1. Levamisole treatments
In the experiments with human preadipocytes we demonstrated for the first time 
that alkaline phosphatase is present in these cells and that increasing 
intracellular lipid accumulation in the absence of ALP inhibitors was associated 
with an increase of alkaline phosphatase enzyme activity paralleling, the data 
from the 3T3 -L1 preadipocytes. The method used in our studies to measure 
adipogenesis was the oil red 0  technique. This technique is based on well 
established protocols (Strutt et al., 1996). Quantitation of lipid accumulation by oil 
red O staining correlates well with the measurements of glycerol 3-phosphate 
dehydrogenase activity (Ramirez-Zacarias et al., 1992).
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The results from our experiments with the human preadipocytes showed similar 
effects of the ALP inhibitors histidine and Phe.Gly.Gly to the results that we 
obtained from the 3T3-L1 experiments. In addition, when we removed the IBMX 
from the human transformation media (data not shown) neither the levamisole 
treated preadipocytes or the non-treated cells showed any sort of differentiation. 
This shows, that as in 3T3-L1 cells, cAMP is an important regulator of 
adipogenesis. Treatment with levamisole increased the activity of the ALP in the 
human preadipocytes. These results conflict with the results from the 3T3-L1 
cells which showed that levamisole inhibits ALP activity but inhibits intracellular 
lipid accumulation in both cell types. However, treatment of the cell extract of 
human preadipocytes with levamisole caused a 50% inhibition of the enzyme. 
Thus, levamisole only inhibits ALP activity in cell extracts and not intact cells but 
is still able to inhibit intracellular triglyceride deposition. This suggests that 
levamisole may be blocking lipid accumulation via a mechanism that does not 
involve ALP. What this mechanism may be is not known. However, the fact that 
levamisole will inhibit ALP in cell extracts but not intact cells suggest that 
levamisole must be interacting with some factor in intact cells that blocks its 
ability to inhibit ALP. Levamisole is known to be an agonist for nicotinic and 
adrenergic receptors (Hsu, 1980) so one hypothesis may be that levamisole 
binds these receptors in intact cells reducing access to the lipid droplet-residing 
ALP. This theory must be explored with the use of antagonists and agonists of 
both receptor types. It is interesting to note that levamisole actually increases 
ALP activity in intact human preadipocytes and this has also been observed in rat
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hepatocytes treated with levamisole (Engelmann and Richardson, 1986). 
Hepatocytes also accumulate intracellular lipid in membrane-bound 
compartments.
Levamisole treatment has shown that differences exist between 3T3-L1 cells and 
human preadipocytes in their response to this ALP inhibitor. The reason for this is 
not known and obviously warrants further investigation.
5.2.1.2. Phe. Gly. Gly
The tripeptide Phe Gly Gly did not show any effect on ALP activity or lipid 
accumulation in any of the preadipocyte preparations. These results parallel 
those from the 3T3-L1 experiments. This data suggests that the ALP isozyme 
present within the 3T3-L1 cells and the human preadipocytes is the tissue non­
specific form. Tissue non-specific ALP is inhibited by levamisole (van Belle,
1976) and histidine (Fishman and Sie, 1971) but not by Phe.Gly.Gly, which is an 
inhibitor of the tissue specific ALP isozymes (Doellgadt and Fishman, 1977). This 
data must be confirmed by performing rtPCR analysis of both these cell types 
using primers specific for the tissue non-specific isozyme of ALP.
5.2.1.3. Histidine
Histidine been shown to suppress food intake through its conversion into 
neuronal histamine (Yoshimatsu, et ai. 2002). Hypothalamic neural histamine 
suppresses food intake through H-1 receptors in the ventromedial hypothalamic
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nucleus and the paraventricular nucleus .Increase in hypothalamic histamine 
concentration elevates peripheral glucose concentration, accelerates lipolysis in 
the adipose tissue, and decreases body temperature (Sakata and Yoshimatsu, 
1977; Yoshaimatsu et al. 2002). In vivo treatment with histamine was able to 
reduce visceral fat predominantly leaving subcutaneous fat unaffected (Masaki, 
2001). Studies have shown that the activation of histamine signalling promoted 
lipolysis through sympathetic nerves (cited in Masaki 2001). Our data suggests 
that histidine may also have direct effects on preadipocytes, not mediated by the 
central nervous system. Histidine blocks intracellular triglyceride accumulation 
and ALP activity in human preadipocytes, confirming the 3T3-L1 studies.
5.2.1.4. Ethnic differences
The prevalence of obesity in South Africa may be high due to urbanization of the 
population (Rossi-Espagnet, 1991). Sedentary life with increased energy intake 
and decreased energy expenditure has caused an increase in the prevalence of 
obesity in both white and black South African societies. It is known that black 
women tend to accumulate less visceral fat, compared with white women. A 
study has also shown that adipocytes collected from black women are more 
insulin resistant than those taken from white females (Buthelezi et al.,2001).
In our study we have seen significant differences between white and black 
women in both alkaline phosphatase activity and adipogenesis .These findings 
support a previous study showing that obesity is more prevalent in middle aged 
black women compared with white women (Puoane et al., 2002) .Increased
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triglyceride deposition in preadipocytes isolated from the mammary tissue 
suggests that in black females there is a greater level of adipogenesis and this 
may partly explain the higher prevalence of obesity in this population. Obviously 
environmental factors must also play a role. Also it is possible that the low 
visceral fat depot size observed in black females is due to preferential storage in 
subcutaneous depots, where the adipogenesis rate is high. Obviously this must 
be confirmed via studies on adipogenesis rate in abdominal subcutaneous fat 
and visceral fat from white and black females. Indeed, researchers have found 
that a failure to differentiate new adipocytes compromises the capacity of lipid 
storage in adipose tissue which in turn leads to an increased fat accumulation in 
other tissues such as visceral fat, skeletal muscle, liver and perhaps pancreatic 
beta cells ( Danforth, 2000).
5.2.1.5. The effect of body site on lipid accumulation and ALP activity
It has been shown that visceral preadipocytes differentiate more slowly compared 
with subcutaneous preadipocytes, indicating that the fat depot origin affects the 
adipogenesis level. Although adipogenesis is delayed in omental compared with 
abdominal subcutaneous preadipocytes, it does eventually proceed. 
Thiazolidinediones (TZD) cause more extensive differentiation of subcutaneous 
than omental cells. In vivo experiments found that TZDs decrease visceral but 
increases subcutaneous fat depot size by acting on adipogenesis (Arner, 2003). 
The new adipocytes resulting from TZD are smaller and more insulin sensitive 
(Arner, 2001). However, despite the differential effect of thiazolidinediones on
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adipogenesis rate in different fat depots, it does not affect the level of PPAR y 
expression in human subcutaneous and omental preadipocytes (Adams et al., 
1997).
Fat cells isolated from different depots of rats and humans differ in size, 
response to insulin and lipolytic agents , lipoprotein lipase release, lipid 
synthetic capacity, fatty acid incorporation and other characteristics (Arner,
1997; Caaserta et al., 2001; Edens et al., 1993; Fried et al., 1993; Montague et 
al., 1997b; Prins and O'Rahilly, 1997).
Other differences in the characteristics of human preadipocytes from various 
depots have been described .It has been found that human visceral 
preadipocytes have a greater susceptibility to apoptosis induced by serum 
deprivation and tumour necrosis factor-alpha than abdominal subcutaneous 
preadipocytes (Niesler et al., 1998). Studies have shown more extensive transfer 
of fatty acids into differentiated human omental than abdominal subcutaneous 
preadipocytes from the same subjects, even after matching cells for lipid content 
, consistent with the greater fatty acid flux in visceral than in subcutaneous fat 
(Casserta et al., 2001).
Preadipocytes from different regions appear to be inherently distinct and studies 
performed with rat preadipocytes support this contention. Preadipocytes cultured 
from perirenai depots were shown to be capable of more extensive replication 
and differentiation in vitro and in vivo than preadipocytes from epididymal depots
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(Djian et al., 1985; Kirkland et al., 1990; Kirkland et al. 1996; Wang et al., 1989). 
Preadipocytes cultured from various depots of rats retained distinct cell dynamic 
and biochemical responses despite exposure to similar hormonal manipulations 
in vivo such as estrogen administration, hypophysectomy, or castration (Kirkland 
et al., 1992; Lacasa et al., 1997). These depot-dependent differences in the 
innate characteristics of adipose cells could contribute to anatomic variation in 
function. Indeed, interdepot variation in cultured rat preadipocyte differentiation 
gene-dependent gene expression has been observed (Kirkland et al., 1996). 
Thus, rat preadipocyte studies are in accord with the hypothesis that inter-depot 
variation in fat cell function reflects differences in the innate characteristics of 
adipose cells themselves. Thus, our study showing differences in adipogenesis 
between human subcutaneous abdominal and mammary gland preadipocytes 
are supported by many other studies. The present study demonstrated that 
mammary gland preadipocytes contained more lipid before induction of 
differentiation than preadipocytes from the abdominal subcutaneous adipose site. 
After 12 days of differentiation however no differences existed in intracellular lipid 
contentAThis data suggests that baseline lipid uptake is greater in mammary than 
subcutaneous abdominal preadipocytes, but that the lipid content in differentiated 
preadipocytes is not different. However, it should be noted that the subjects from 
whom mammary adipose tissue was obtained had a lower BMI, than subjects 
from whom subcutaneous abdominal adipose tissue was taken. Therefore, we 
cannot rule out the possibility that the differences observed in preadipocyte lipid 
content are due to differences in body mass. However, this is unlikely because
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we were unable to demonstrate any correlation between BMI and the lipid 
content of the preadipocytes taken from either body site .
Subcellular localization of ALP
Alkaline phosphatase is normally located either on the plasma membrane (Harris, 
1990; DePierre and Karnovsky, 1973) or on secretary vesicles (Detmers et al., 
1995) and is anchored to cell membranes via glycosylphosphatidylinositol (GPI) 
(Low and Saltiel, 1988; Kihn et al., 1990). The present study describes the 
association of alkaline phosphatase with intracellular lipid droplets and in light of 
the large body of evidence demonstrating that alkaline phosphatase is a 
membrane-associated enzyme (Harris, 1990; DePierre and Karnovsky, 1973; 
Detmers et al., 1995; Low and Saltiel, 1988; Kihn et al., 1990) it is presumed that 
alkaline phosphatase is attached to the membrane of these organelles. This is 
the first study to demonstrate that alkaline phosphatase is not associated with 
only secretary vesicle membranes or the plasma membrane. Studies have shown 
that the membrane of lipid droplets is closely associated with that of the 
endoplasmic reticulum (Blanchette-Mackie et al., 1995; Targett-Adams et al., 
2000), which, along with the Golgi system is also the source of secretory 
granules (Stephens and Pepperkok, 2001). The association of ALP with the 
cytoplasmic lipid droplets is also suggestive of ALP playing a role in intracellular 
triglyceride accumulation, as confirmed in the ALP inhibitors studies.
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5.2.2. The effect of weight on ALP activity and other liver enzymes
The existence of ALP in human preadipocytes prompted an investigation of the 
possible link between serum ALP levels and BMI. Total ALP levels and levels of 
bone ALP were measured in 100 African subjects of varying BMI. Liver ALP 
levels were estimated by taking the difference between the values for total ALP 
and bone ALP. Serum levels of liver enzymes and products of hepatic synthetic 
pathways were also assessed to ensure no volunteers had any liver pathology, 
as this would contribute to elevated ALP levels in the blood. Univariate 
regression analysis showed that serum total ALP levels correlated with age and 
weakly with BMI.
Multivariate analysis demonstrated that the relationship between BMI and ALP 
levels were probably due to age acting as a confounding variable. However, 
when subjects were divided into lean, overweight and obese groups and ALP 
levels analysed using ANCOVA adjusted for age, sex and BMI there was a 
significantly higher ALP level in obese than lean subjects. No such relationship 
was found for the other liver function tests suggesting that adipose tissue rather 
than liver tissue may be contributing to this relationship. Furthermore, the 
estimated liver ALP in serum was also found to be higher in obese than lean 
subjects, whereas bone ALP was not. Another study has also found positive 
relationships between serum total ALP and BMI (Golik et al, 1991). Liver 
enzymes, particularly ALT have also been found to increase with increasing BMI 
and WHR, and the hypothesis has been that this is due to fat deposition in the 
liver (steatohepatitis). Our data confirms the relationship between serum ALT
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levels and WHR and also weaker relationships are noted for albumin, and total 
bilirubin with WHR. Thus, all liver function tests that have been shown to 
correlate with BMI and WHR in other studies have been shown to correlate with 
WHR in this study. This suggests that liver products found in the serum are 
released due to increased hepatic fat deposition, which in turn is related to 
abdominal obesity. ALP levels however, only show an association with increased 
BMI and not even a weak association with WHR.
Granted this relationship is only observed when subjects are grouped according 
to BMI, however it is suggestive of a relationship between total body fat mass 
and serum ALP levels, rather than of a relationship between liver derived ALP 
and abdominal obesity. The reason for the lack of a correlation between serum 
ALP and BMI in multiple regression analyses but the existence of a relationship 
in ANCOVA is difficult to explain. It may suggest a non-linear relationship 
between these 2 variables, and one possible explanation for this may be that 
ALP is derived from multiple sources within the body. The lack of a relationship 
between bone ALP and BMI suggests that the isoform in the serum is not the 
bone form. The inhibitor studies have shown that the isozyme in human 
preadipocytes is the tissue nonspecific form, which consists of isoforms from the 
liver, bone and kidney that differ by glycosylation pattern. ALP from the kidney is 
not found in serum and therefore the isoform in preadipocytes may be the liver 
isoform. This must be confirmed by gel electrophoretic analysis of ALP isolated 
from human preadipocytes.
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Conclusions
Alkaline phosphatase has been the subject of intensive research due to its 
wide tissue distribution (McComb, 1979), clinical utility as a marker of liver 
and bone disorders (Wolf, 1986) and its early, controlled expression during 
defined stages of mammalian embryogenesis (McComb, 1979; Hahnel et al., 
1990; McDougall et al., 1998). However, this is the first study to demonstrate 
a possible role for alkaline phosphatase in intracellular lipid accumulation during 
preadipocyte differentiation. This is important because studies have suggested 
that alkaline phosphatase may be involved in organogenesis (Hillman et al., 
1975; McCulloch et al., 1990) and cell differentiation (Andracchi and Korte, 1991; 
Feldbush and Lafrenz, 1991) and the present study supports these hypotheses 
with strong in vitro evidence. The 3T3-L1 cell line may therefore represent a very 
good model for the study of the role of alkaline phosphatase in the control of 
cellular differentiation and may also be useful in identifying the endogenous 
ligands of the enzyme, which are as yet unknown (McComb et al., 1979; Harris,
1990).
The present study has also demonstrated that ethnic differences exist in 
the level of activity of ALP in preadipocytes and these differences are paralleled 
by similar differences in lipid deposition. The role of ALP in the control of 
intracellular triglyceride accumulation in human preadipocytes is however, 
unclear. Histidine did inhibit both ALP activity and lipid deposition whereas 
levamisole increased ALP activity but decreased lipid levels. In the 3T3-L1 cells 
levamisole inhibited ALP activity and blocked lipid build-up. These data
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demonstrate that levamisole has different effects on ALP activity in these two cell 
types but similar effects on lipid accumulation. This demonstrates that the 
relationship between ALP activity, as modified by levamisole and intracellular 
lipid deposition, differs in the two cell types.
The immunocytochemical studies show that ALP is localised to the lipid droplet in 
both 3T3-L1 cells and human preadipocytes and this is suggestive of a role for 
ALP in controlling cellular triglyceride accumulation.
The presence of ALP activity in 3T3-L1 cells and preadipocytes from mammary 
gland tissue and subcutaneous abdominal fat depot suggest that ALP expression 
is a common feature of cells that accumulate triglyceride in cytoplasmic lipid 
droplets.
The higher levels of ALP activity in serum from obese than lean subjects 
suggests that adipose tissue as well as liver and bone may contribute to the ALP 
measured in human serum.
Future Studies
The results presented in this thesis represent preliminary studies on the possible 
involvement of alkaline phosphatase in intracellular lipid deposition within 
preadipocytes. The present study used inhibitors of ALP that are non-specific and 
have other side effects that may also induce inhibition of lipid accumulation. It is 
therefore important to use techniques that specifically knock out ALP gene 
expression to confirm that ALP does play a role in lipid deposition. Techniques 
such as the use of small inhibitory RNA (siRNA) would be useful in this regard. In
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addition, the inhibitor studies suggest that the ALP isozyme present in 3T3-L1 
and human preadipocytes is the tissue non-specific form. This must be confirmed 
using PCR analysis.
Levamisole was shown to inhibit lipid accumulation in human preadipocytes but 
this did not involve inhibition of ALP activity. This suggests that levamisole is 
affecting lipid deposition independently of any effect on ALP activity. Levamisole 
is known to have adrenergic and nicotinic effects (Hsu, 1980) and therefore it 
would be interesting to study the effect of levamisole on lipid accumulation in 
human preadipocytes in the presence of antagonists of adrenergic and nicotinic 
receptors. Furthermore, levamisole inhibited adipogenesis in the 3T3-L1 cell line 
in parallel with inhibition of ALP activity. This demonstrates differential effects of 
levamisole on ALP activity in human and 3T3-L1 preadipocytes and it would 
therefore be interesting to investigate the effects of levamisole on gene and /or 
protein expression in both cell types using microarray and proteomic technology.
These studies demonstrate that ALP inhibitors block intracellular lipid deposition 
within preadipocytes but they do not prove that adipogenesis has been inhibited. 
This must be studied by measuring the expression of molecules that are known 
to be upregulated during adipogenesis e.g. PPARgamma, fatty acid binding 
protein-1 (FABP1) and glycerol 3-phosphate dehydrogenase (Gregoire et al., 
1998).
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If we can confirm that ALP does play a direct role in the control of intracellular 
lipid deposition then it would be important to determine whether ALP inhibitors 
can block adipose tissue hypertrophy in rodent models of obesity. Furthermore, 
the present study has only analysed ALP activity in preadipocytes and has not 
investigated the level of this enzyme in mature adipocytes. Studies should 
therefore be performed on murine and human mature adipocytes to determine 
the activity of ALP and to relate this to the level of obesity.
We have shown that ALP activity is present in preadipocytes isolated from both 
mammary tissue and the subcutaneous abdominal fat depot. It has also been 
demonstrated that ethnic differences in the level of adipogenesis is mirrored by 
higher ALP activity in preadipocytes isolated from mammary tissue in black 
compared to white females. It would be interesting to investigate whether ethnic 
differences also exist for preadipocytes taken from the visceral and 
subcutaneous fat depots as studies have shown that obesity is more prevalent in 
South African black than white females (Puoane et al., 2002) and the former 
group tend to have lower levels of visceral fat compared to the latter, but greater 
gluteo-femoral fat depot size.
Adipocytes are not the only cells that accumulate lipid within membrane-bound 
intracellular compartments. Hepatocytes, adrenal cortical cells and the Leydig 
cells within the testes also contain lipid droplets (Greenberg et al., 1991). In 
addition, gut enterocytes possess membrane-bound lipid droplets that have
165
intestinal ALP bound to their surface (Zhang et al., 1996). Hepatocytes and 
adrenal cortical cells are also known to express ALP and the protein 
components of the membrane surrounding the lipid droplets in these different cell 
types share common features, notably the presence of perilipin (Greenberg et al.,
1991). Future studies should therefore determine whether ALP activity is also 
associated with the lipid droplets found in these different cell lineages, and if so 
this would suggest that ALP is an essential component of all cells that 
accumulate intracellular lipids.
Drawbacks of present study
1. This study used pharmacological inhibition of ALP. The inhibitors used may 
also have non specific effect on adipogenesis independent of their effects on 
ALP. The specific inhibition of ALP, should therefore be investigated using 
molecular techniques such as small interfering RNA (siRNA).
2. The oil red O technique for assessing adipogenesis is a commonly used 
method, however, it is not the most sensitive technique available for measuring 
adipogenesis. The measurement of glycerol 3- phosphate dehydrogenase should 
be used in future studies.
3. ALP inhibitory studies, have shown that the isotype present in preadipocyte is 
tissue non-specific ALP and this must be confirmed using PCR analysis.
4. The measurement of ALP levels in serum is hindered by the fact that it is not 
possible to distinguish intestinal ALP from liver ALP using a simple ELISA. Future 
studies should be performed in which total body fat levels are measured
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accurately and correlated with bone, liver and intestinal serum ALP levels. The 
three ALP forms found in serum may be measured using gel electrophoresis in 
conjunction with densitometric scanning of the gels.
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Patient
No
Ethnicity Age Weight
(Kg)
Height
(M)
BMJ ALP inhibitors used 
with preadipocytes
1 White 42 74 1.68 26.1 Leva
2 White 39 65 1.60 25.6 Leva.
3 White 43 59 1.63 22.2 Leva.
4 White 48 71 1.65 26.1 Leva.
5 White 35 70 1.65 22.7 Leva.
6 White 42 73 1.70 25.3 Leva.
7 White — — — — Leva
8 White — — — — Leva
9 White 47 74 1.70 25.6 Hist.
10 White 51 71 1.68 25.1 Hist.
11 White 42 63 1.65 23.1 Hist.
12 White 41 74 1.70 25.6 Hist + Phe Gly Gly.
13 White 51 71 1.68 25.1 Phe Gly Gly
14 White 45 68 1.71 23.2 Phe Gly Gly
15 White 39 67 1.68 23.9 Phe Gly Gly
16 Black 51 63 1.60 24.6 Leva.
17 Black 46 70 1.73 23.4 Leva
18 Black 55 68 1.61 26,2 Leva.
19 Black 53 65 1.58 26.0 Leva
20 Black 44 60 1.65 22.0 Leva
21 Black 39 70 1.62 26.7 Leva
22 Black 41 60 1.65 22.0 Leva
23 Black 46 74 1.68 26.2 Leva.
24 Black — — — Leva.
25 Black 41 67 1.60 26.2 Hist + Phe Gly Gly
26 Black 38 71 1.66 25.8 Hist + Phe Gly Gly
27 Black 46 68 1.63 25.6 Hist + Phe Gly Gly
28 Black 45 65 1.60 25.4 Hist + Phe Gly Gly
Table 1. Details of patients from whom mammary gland adipose tissue was 
obtained.
Leva = levamisole 
Hist = histidine
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Patient's
No
Ethnicity Age Weight Height BMI ALP inhibitors used 
on preadipocytes
1 Black 54 95 1.65 34.9 Leva
2 Black 48 93 1.64 34.7 Leva
3 Black 42 75 1.60 29.3 Leva
4 Black 35 73 1.52 31.6 Leva
5 Black 47 100 1.67 36.0 Hist and Leva
6 Black 42 109 1.64 40.7 Hist
7 Black 42 78 1.48 35.6 Hist
8 Black 39 94 1.63 35.5 Hist
9 Black 47 130 1.56 53.5 Hist
10 Black 58 124 1.60 48.4 Hist
11 Black 54 100 1.76 32.5 Hist
12 Black 47 79 1.47 36.6 Hist
13 Black 49 121 1.57 49.2 Hist
Table 2. Details of the subjects from whom subcutaneous abdominal 
adipose tissue was obtained.
Leva = levamisole 
Hist = histidine
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1. Data for ALP inhibitor studies in 3T3-L1 cells (means ± SEMs)
U n its : A LP activ ity  = m U /m g protein  
Lipid accum ulation  = O D  units
1.1 The effect o f levam iso le  on ALP activ ity  in 3T3-L1 cells (See figure  4 .2A ).
D ay 0 Day 3 Day 7 Day 11
W ith  levam isole 1.90±0.62 13.77±8.50 11.30±3.60 10.44±3.90
W ithou t levam iso le 1.90±0.62 10.94±2.80 17.16±6.0Q 23.00±9.20
1.2 The e ffect o f levam iso le  on lipid accum ulation  in 3T3-L1 cells (See figure  4 .2B ).
DayO Day 3 Day 7 Day 11
W ith  Levam isole 0.29±0.05 0.35±0.07 0.47±0.11 0.59±.010
W ithou t Levam iso le 0.2910.05 0.44+0.11 0.65+0.10 0.90±0.14
1.3 The effect o f Phe G ly G ly on ALP activ ity  in 3T3-L1 C ells  (See figure  4 .3A )
Day 0 Day 7 Day 11
W ith  Phe. G ly .Gly 1.60±0.50 30.6H.6 56.719.8
W ithout Phe. G ly. G ly 1.60+0.50 24.913.3 71.7+4.9
1.4 The e ffect o f Phe G ly G ly  on lipid accum ulation  in 3T3-L1 cells  (See figure  4  .3B).
Day 0 Day 7 Day 11
W ith  Phe.G ly. Gly 0.3110.05 0.7010.15 0.4910.01
W ithou t Phe.G ly  .Gly 0.3110.05 0.5610.08 0.50 10.01
1.5 The e ffect o f h istid ine on A LP  activity  in 3T3-L1 cells  (See figure  4 .4A ).
Day 0 Day 3 Day 7 Day 11
W ith  H istidine 1.6010.36 2.910.7 1.910.31 1.910.56
W ith o u t H istid ine 1.6010.36 9.211.6 22.811.6 39.119.6
1.6 The e ffect o f h istid ine on lipid accum ulation  in 3T3-L1 cells  (See figure  4 .4B ).
D ay 0 Day 3 D ay 7 D ay 11
W ith  H istidine .151.011 .181.005 .221.014 .251.020
W ith o u t H istdine .151.011 .31.005 471.015 .621.008
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2. Data for transformation medium studies in 3T3-L1 cells (means ± SEMs)
2.1 The e ffect o f rem oving  IB M X  or Insulin  or D EXA on lip id  accum ulation  in 3T3 - L1 cells  
(See figure  4.5A ).
Day 0 Day 3 Day 6
IBM X 0 0.16±0.02 0.19±0.02 0.22±0.01
IN SU LIN  0 0.16±0.G2 0.28±0.07 G.47±0.14
N O R M A L M ED IA 0.16±0.02 0.36±0.04 0.55±0.08
DEXA 0 0.16±0.02 0.35±0.05 0.53±0.08
2.2 The e ffect o f rem oving  IB M X or Insulin  or DEXA on ALP activ ity  in 3T3-L1 cells  (See  
figure  4 .5B ).
Day 0 Day 3 Day 6
IB M X 0 1.39±0.38 1.75±0.34 2.75±1.70
IN SU LIN  0 1.39±0.38 11.97±4.0G 16.9±7.2
N O R M A L M ED IA 1.39±0.38 14.21±4.10 30.0+4.4
DEXA 0 1.39±0.38 13.07±3.00 31.0±7.0
2.3 The e ffect o f level o f concentration  o f DEXA and IBM X on lip id  accum ulation  in 3T3 -L 1  
cells  (See figure  4 .6A ).
D ay 0 Day 3 Day 6
0.22pM  D EX:0.17pM  IB M X 0.17±0.01 0.18±.002 0.21±0.01
0.22pM  D EX:0.5pM  IB M X 0.17±0.01 0.23±.010 0.27±0.03
0.22pM  D EX:1.5pM  IB M X 0.17±0.01 0.29±.037 0.31+0.05
0.66pM  D EX:0.5pM  IB M X 0.17±0.01 0.30±.033 0.33±0.05
0.07pM  DEX:0.5pM  IB M X 0.17±0.01 0.24±.025 0.27±0.04
0.023pM  D EX:0.5pM  IB M X 0.17±0.01 0.25±.026 0.29±.016
2.4  The e ffect o f level o f concentration  o f DEXA and IBM X on A LP activ ity  in 3T3-L1 cells  
(See figure  4 .6B ).
Day 0 Day 3 Day 6
0.22pM  D EX:0.17pM  IB M X 0.79±0.11 3.29±0.57 4.70±0.88
0.22pM  D EX:0.5pM  IB M X 0.79±0.11 10.40±2.85 15.50±1.86
0.22pM  DEX:1.5pM  IBM X 0.79±0.11 16.80±1.07 31.21+4.42
0.66pM  DEX:0.5pM  IBM X 0.79±0.11 13.73±1.02 20.21±2.41
0.07pM  D EX:0.5pM  IB M X 0.79±0.11 8.02±1.31 14.31±3.14
0.023pM D EX:0.5pM  IBM X 0.79±0.11 10.60±2.36 16.55±1.41
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3. Data for ALP inhibitor studies with preadipocvtes taken from mammary 
gland tissue (means ± SEMs)
3.1 The e ffect o f levam iso le  on lipid accum ulation o f m am m ary tissue preadipocytes taken  
from  w h ite  w om en  (See figure  4.7A).
Day 0 Day 12
W ith Levam isole 0.26±0.01 0.35±0.01
W ithout Levam iso le 0.26±0.G1 0.50±0.02
3.2  The e ffect o f levam iso le  on ALP activity  o f m am m ary tissue pread ipocytes taken from  
w hite  w om en (See fig u re  4 .7B ).
Day 0 Day 12
W ithout Levam iso le 37.9±8.0 133.8±20.9
W ith  Levam isole 37.9±8.0 230.9±50.5
3.3 The e ffect o f levam iso le  on lip id accum ulation o f m am m ary tissue pread ipocytes taken  
from  black w om en  (See figure  4 .8 A).
D ay 0 Day 12
W ith  Levam isole 0.31±0.01 0.40±0.01
W ithou t L evam iso le 0.31±0.01 0.7Q±0.01
3.4 The e ffect o f levam iso le  on A LP activity  o f m am m ary tissue pread ipocytes  taken from  
black w om en (See  fig u re  4 .8B ).
Day 0 Day 12
W ithout Levam iso le 135.0±16.5 269.9± .41.5
W ith  Levam isole 135.0±16.5 444.4±86.4
3.5 The e ffect o f Phe G ly  G ly  on lipid accum ulation  o f m am m ary tissu e  preadipocytes  
taken from  w h ite  w om en  (See figure  4.9A ).
D ay 0 Day 12
W ithout Phe.G ly .G ly 0.21±0.01 0.44±0.06
W ith  Phe.G ly .G ly 0.21±0.01 G.43±0.07
3.6 The e ffect o f P he  G ly  G ly  on A LP  activ ity  o f m am m ary tissue taken from  w h ite  wom en  
(See figure  4.9B ).
D ay Q Day 12
W ithout Phe.G ly .G ly 45.3±5.1 157.2±12.5
W ith  Phe.G ly .G ly 45.3±5.1 1 43 .3 i16 .6
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3 .7  T h e  e ffe c t  o f  P h e  G ly  G ly  o n  lip id  a c c u m u la tio n  o f  m a m m a ry  t is s u e  p re a d ip o c y te s
ta k e n  fro m  b la c k  w o m e n  (S e e  f ig u re  4 .10 A ).
Day 0 Day 12
W ithou t Phe.G ly .G ly 0.29±0.01 0.82±0.04
W ith  Phe.G ly .G ly 0.29±0.01 0.81±0.04
3.8 The e ffec t o f Phe G ly  G ly on ALP activity  o f m am m ary tissu e  pread ipocytes taken from  
black w om en (See figure  4.1 OB).
Day 0 Day 12
W ith o u t P he.G ly .G ly 143.4±10.9 321.7±28.7
W ith  Phe.G ly .G ly 143.4±10.9 320.9±25.4
3.9 The e ffect o f h is tid ine  on lip id  accum ulation o f m am m ary tissu e  preadipocytes taken  
from  w h ite  w om en  (See figure  4.11 A).
D ay 0 Day 12
W ith  H istid ine 0.24±0.02 0.30±0.04
W ith o u t H is tid ine 0.24±0.02 0.51±0.04
3.10 The e ffect o f h istid ine on A LP activity o f m am m ary tissu e  pread ipocytes taken from  
W hite  w om en (See figure  4.11 B).
Day 0 Day 12
W ith  H istid ine 3 1 .5±11.2 9.1±2.0
W ith o u t H is tid ine 31 5 ±1 1.2 97.6±24.9
3.11 The e ffect o f h istid ine on lipid accum ulation o f m am m ary tissu e  preadipocytes taken  
from  black w om en  (See figure  4 .1 2A).
D ay 0 Day 12
W ith  H istid ine 0.29±0.005 0.38±0.02
W ithou t H istid ine 0.29±0.005 0.87±0.03
3.12 The e ffec t o f h istid ine on A LP  activity  o f m am m ary tissu e  pread ipocytes  taken from  
black w om en (See figure  4 .1 2B).
Day 0 Day 12
W ith  H istid ine 143.4±10.8 12.55±2.81
W ithou t H istid ine 143.4±10.8 305.8±22.9
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4. Data on lipid accumulation and ALP activity in mammary tissue
preadipocvtes isolated from white and black females (meanstSEMs)
4.1 Ethnic d iffe rences  in lipid accum ulation during levam isole  treatm ent (See figure  4 .13A ).
Day 0 Day 12
W ith  Levam iso le  W hite 0.26±0.01 0.35±0.01
W ithou t Levam iso le  W hite 0.26±0.01 0.50±0.01
W ith  Levam iso le  B lack 0.31±0.01 0.40±0.01
W ithou t L evam iso le  B lack 0.31±0.01 0.70±0.01
4.2  E thnic d iffe rences  in A LP  activity  during levam isole  trea tm en t (See figure 4 .1 3B).
Day 0 Day 12
W ith o u t Levam iso le  W hite 37.89± 8.02 133.7± 21.0
W ith  Levam iso le  W hite 37.89± 8.02 230.8±50.5
W ithou t Levam iso le  B lack 135.0±16.5 269.9±41.4
W ith  Levam iso le  B lack 135.0±16.5 444.4±86.3
4.3  Ethnic d iffe rences  in lip id accum ulation during Phe G ly G ly  trea tm en t (See figure  
4.14A ).
Day 0 Day 12
W ith o u t Phe.G ly .G ly  W h ite 0.21±0.01 0.44±0.06
W ith  Phe.G ly .G ly  W hite 0.21±0.01 0.43±0.07
W ith o u t P he.G ly .G ly  B lack 0.29±0.005 0.82±0.04
W ith  Phe.G ly .G ly  B lack 0.29+0.005 0.81±0.04
4 .4  Ethnic d iffe rences  in A LP  activity  during Phe G ly  G ly  trea tm en t (See figure  4 .14B ).
Day 0 Day 12
W ithou t P he.G ly .G ly  W h ite 45.32±5.12 157.1±12.5
W ith Phe.G ly .G ly  W hite 45.32±5.12 143.3±16.6
W ithou t P he.G ly .G ly  B lack 143.4±10.8 321.7±28.7
W ith  Phe.G ly .G ly  B lack 143.4±10.8 320.9±25.4
4 .5  Ethnic d iffe rences  in lipid accum ulation during h istid ine trea tm en t
Day 0 Day 12
W ith  H istid ine W h ite 0.24±0.02 0.30±0.04
W ithout H is tid ine  W hite 0.24±0.02 0.51±0.04
W ith  H istid ine B lack 0.29±0.005 0.38±0.02
W ithou t H istid ine B lack 0.29±0.005 0.87±0.03
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4 .6  E th n ic  d iffe re n c e s  in A L P  a c tiv ity  d u rin g  h is tid in e  tre a tm e n t (S e e  f ig u re  4 .1 5 B ).
Day 0 Day 12
W ith  H is tid ine  W hite 31.52±11.22 9.1012.02
W ith o u t H is tid ine  W hite 31.52±11.22 97.60124.94
W ith  H is tid ine  B lack 143.4110.9 12.5512.81
W ith o u t H is tid ine  B lack 143.4110.9 305.8122.9
5. Data for ALP inhibitor studies with preadipocvtes taken from 
subcutaneous abdominal tissue of black females (means ± SEMs)
5.1 The e ffec t o f levam isole  on lipid accum ulation  o f abdom inal tissue  taken from  black  
w om en (See figure  4 .16A).
Day 0 Day 12
W ith  Levam iso le 0.1810.03 0.3510.02
W ith o u t Levam iso le 0.1810.03 0.5710.03
5.2 The e ffec t o f levam isole  on ALP activ ity  o f abdom inal tissue  taken from  black w om en  
(See fig u re  4 .1 6B).
Day 0 Day 12
W ith o u t Levam iso le 108.8112.6 380.816.8
W ith  Levam iso le 108.8H2.6 780.11174.9
5.3 The e ffec t o f h istid ine on lipid accum ulation  o f abdom inal tissue  taken from  black  
w om en (S ee  figure  4 .17A).
Day 0 D ay 12
W ith  H istid ine 0.2710.02 0.3810.04
W ith o u t H is tid ine 0.2710.02 0.7110.06
5.4  The e ffec t o f h istid ine on ALP activity  o f abdom inal tissue  taken from  black w om en  
(See fig u re  4 .1 7B).
Day 0 D ay 12
W ith  H istid ine 140.318.3 44.0121.6
W ithou t H is tid ine 140.318.3 381.2172.7
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6. Data on lipid accumulation and ALP activity in mammary and abdominal
tissue preadipocvtes isolated from black females (means±SEMs)
6.1 The e ffec t o f s ite  o f origin o f preadipocytes on lipid accum ulation  during levam isole  
trea tm en t (See figure  4 .1 8A).
Day 0 Day 12
W ith  Levam iso le  M am m ary 0.3110.01 0.4010.01
W ith o u t Levam iso le  M am m ary 0.3H0.01 0.7010.01
W ith  L evam iso le  A bdom inal 0.1810.03 0.3510.02
W ith o u t L evam iso le  A bdom inal 0.1810.03 0.57+0.03
6.2 The e ffec t o f the s ite  o f origin o f pread ipocytes on A LP activ ity  during levam iso le  
trea tm en t (See figure  4 .1 8B).
Day 0 Day 12
W ith o u t Levam iso le  M am m ary 135.0116.5 269.9141.5
W ith  L evam iso le  M am m ary 135.0116.5 444.4186.4
W ith o u t L evam iso le  A bdom inal 108.818.3 380.8121.6
W ith  Levam iso le  A bdom inal 108.818.3 780.1172.7
6.3 The e ffec t o f the s ite  o f origin o f pread ipocytes on lipid accum ulation  during h istid ine  
trea tm en t (See figure  4 .1 9A).
Day 0 D ay 12
W ith  H is tid ine  M am m ary 0.2910.005 0.3810.02
W ith o u t H is tid ine  M am m ary 0.2910.005 0.8710.03
W ith  H is tid ine  A bdom inal 0.2710.02 0.3810.04
W ith o u t H is tid ine  A bdom inal 0.2710.02 0.7110.06
6.4  The e ffec t o f the  s ite  o f origin o f pread ipocytes on A LP  activ ity  during h istid ine  
trea tm en t (S ee  figure  4 .1 9B).
Day 0 D ay 12
W ith  H istid ine M am m ary 143.3110.8 12.5512.81
W ith o u t H is tid ine  M am m ary 143.3110.8 305.7122.9
W jth  H istid ine A bdom inal 140.318.3 44.02121.60
W ith o u t H is tid ine  A bdoninal 140.318.3 381.2172.7
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